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 Candida auris is an emerging fungal pathogen that commonly causes nosocomial blood 
infections in the immunocompromised. Three factors make this emerging pathogen a global threat. 
First, it is frequently misidentified by commonly used diagnostic platforms. Second, it is able to survive 
for weeks on fomites. Third, it is almost always drug resistant, sometimes to all three classes of 
antifungal drugs used to treat Candida infections. The objectives of this study are three-fold. First, two 
existing methods, population estimation using absorbance-based standard curves and methylene blue 
viability staining, were investigated as to application in determining Candida auris cell population size 
and viability, respectively. Both the spectrophotometric study and methylene blue staining were 
successfully applied to C. auris concentrations. A standard curve plotting absorbance to concentration 
were constructed for several organisms for standardizing inoculum for subsequent assays. Second, a 
description of the basic metabolic capabilities of Candida auris to assimilate a variety of chemicals as a 
sole source of carbon or nitrogen was determined and compared to related yeasts. Candida auris 
displayed a unique pattern of carbon and nitrogen assimilation as compared to the other, related 
species. This included several carbon sources that may have future utility in a diagnostic media. Several 
isolates of C. auris were also examined using the Biolog YT plate for yeast identification, which operates 
under a similar principle. Although the organism is absent from database and thus misidentified as one 
of two organisms in all cases, a significant amount of carbon utilization data was added to the results of 
the previous study. Third, the antifungal activities of select essential oils were tested against C. auris. 
This was followed by testing the interaction of the three most effective oils with four commonly used 
antifungal drugs. Several of the essential oils displayed the ability to inhibit the growth or even kill C. 
auris, Candida lusitaniae, and Saccharomyces cerevisiae when in direct contact. The three most effective 
oils were those of lemongrass, clove bud and cinnamon bark. These three oils even retained some 
antifungal activity in vapor-phase. These were also the oils used in combination with fluconazole, 
amphotericin B, flucytosine and micafungin. While cinnamon bark oil displayed little interaction with the 
drugs, lemongrass oil displayed positive or neutral interactions with all four drugs, while clove bud oil 
had mixed results. The combination of clove bud oil and amphotericin B resulted in an antagonistic 
outcome, whereas it showed no improved effect when combined with micafungin but displayed positive 




Drug Resistant Pathogens 
 
Drug-resistant pathogens are becoming an increasing problem [1]. Pathogens once easily 
treated are becoming increasingly more difficult to treat due to multi-drug resistance, leading to an 
increased incidence of debilitating and often fatal infections. Adding to this problem, the rise in 
conditions compromising the immune system are promoting infection by opportunistic pathogens [2]. 
Immune compromising conditions are caused by a variety of factors, including primary genetic 
disorders, acquired secondary diseases, and human interventions that suppress the immune system, like 
chemotherapy [3, 4]. All these conditions open the possibility of infection by organisms previously 
thought to be harmless, including many fungi. One report shows a threefold increase in deaths from 
invasive fungal infections between 1981 and 1996 [2]. Current estimates place the global incidence of 
several invasive fungal infections at 100,000 cases or more each year (Table 1) [5]. 

























Among these fungal opportunists are species like Candida albicans and Aspergillus fumigatus 
[2]. These organisms are ubiquitous in the environment and some are even normal commensals, or 
organisms that harmlessly colonize various parts of the body [6, 7]. Individuals are often at risk of 
acquiring these organisms from their surroundings or when they come into contact with asymptomatic 
carriers, in addition to those showing clear signs of infection. For immunocompromised individuals, the 
environment and colonized individuals are dangerous reservoirs for fungal pathogens. When exposed, 
healthy individuals’ immune systems are able to prevent clinical infection by these organisms. In this 
case, the organism is either completely cleared or maintains a presence as a commensal. While some of 
these infections are non-life-threating, some can escalate to systemic infections in the 
immunocompromised when their immune systems cannot eliminate the infection [8]. If the organisms 
can gain a foothold, they can then grow unabated, leading to serious complications and often death if 
not treated promptly [2]. Many times, these infections occur in healthcare settings where both 
vulnerable people and potential pathogens are concentrated in high densities. Those who do seek 
treatment often receive antifungal drugs and have a much higher chance of recovery. Even with 
treatment, these infections can be deadly. Multiple studies report mortality rates as high as 50% in 
patients treated for invasive fungal infections [9, 10]. 
Antifungal Drugs 
 
To date, only three classes of antifungals have been developed that are considered safe and 
widely used to treat invasive fungal infections. Echinocandins (eg. micafungin) inhibit fungal cell 
membrane formation by disrupting synthesis of the structural component 1,3-β-d glucan [11]. Azoles 
(eg. fluconazole) inhibit the biosynthesis of the cell membrane component ergosterol while polyenes 
(eg. amphotericin B) bind to membrane ergosterol to induce pores and cause cell death through leakage 
of cytosolic components [11]. In addition to these, a nucleoside analog, flucytosine (5-fluorocytosine or 
5-FC), is sometimes used in combination with other drugs as a treatment, and acts by inhibiting 
synthesis of pyrimidine and their incorporation into larger nucleic acids [11, 12]. Two metrics that are 
frequently utilized to assess the effectiveness of antifungals are minimum inhibitory concentration (MIC) 
and minimum fungicidal concentration (MFC). The MIC is the minimum concentration required to totally 
inhibit the growth of a starting inoculum. The MFC is the minimum concentration required to totally kill 
the starting inoculum. Despite the presence of multiple treatment options, resistant organisms exist for 
all three classes of these drugs [13, 14]. Researchers have discovered many modes of resistance, 
discussed briefly below and in-depth elsewhere [15]. This presents a need for additional therapeutic 
options for these deadly infections.  
Although research to develop effective treatment options is ongoing, this progress is slow for 
several reasons. Development is very expensive due to the extensive testing required by the Food and 
Drug Administration in the United States, among other agencies [16]. These requirements are present to 
ensure the safety of the drugs before administering them to the public. Development of antifungal drugs 
is often more complicated than when developing antibiotics to treat bacterial infections. Much of this 
problem is rooted in the genetic and cellular similarity between fungal pathogens and their hosts. As 
fungi and mammals are both eukaryotic, several cell structures are conserved in both groups of 
organisms. Important cellular structures synonymous with the antifungal drug targets are present and 
can be damaged by the antifungals, and therefore selective toxicity against the pathogen without 
causing harm to the host is problematic. As such, the drugs used to treat fungal infections are often 
harmful to the patient, especially at the elevated doses needed to treat resistant strains [17]. This 
similarity limits the availability of drug targets when developing new drugs, exacerbating the problem. 
Even though they are declared safe to use, they often have significant side-effects that may be 
unacceptable to certain patients [17]. Another issue is a lack of a singular codified method for 
determining the effectiveness of an antimicrobial. Since multiple methods are in common use, 
inconsistent results are often obtained. When the methods are not properly defined, other researchers 
can misinterpret these results. Combined, these problems not only lead to the slow development of new 
treatment options, but also place a large burden of cost on the patients in need of these drugs. Thus, 
there exist a need for cheap and effective treatment options to supplement the existing methods. 
Antifungal Resistance 
 
Several mechanisms of antifungal drug resistance exist. These can be innate to the organism or 
acquired through gene transfer. When a pathogen is innately resistant to an antifungal and a potential 
host is repeatedly treated with that antifungal, a selective pressure is placed that allows the drug-
resistant organism to outperform the other organism competing for the host [18]. This allows the drug-
resistant organism to proliferate and possibly transfer the resistance genes to non-resistant organisms. 
In acquired resistance, the drug-resistant fungus acquires the genetic material containing the resistant 
genes. While there is some evidence of horizontal gene transfer, it is little understood in yeasts and 
happens rarely [19]. The most common mode of gene transfer is through mating with other members of 
its species [20].  
Regardless of where the resistance comes from, many mechanisms exist by which this resistance 
takes effect. These mechanisms are generally recognized to rely on one of several strategies. One 
strategy is to alter the target of the drug [15]. By altering the target, the drug cannot bind effectively and 
is unable to affect the organism. Another strategy involves creating a workaround of the drug’s target. If 
the drug blocks one metabolic pathway, the second strategy allows the organism to bypass the pathway 
by using an alternative one [15]. A common strategy is to effectively lower the bioavailability of the 
antifungal. Efflux pumps transport drugs out of the cell and prevent a dangerous concentration from 
building up [15]. Some organisms overexpress the number of drug targets so that the target’s function is 
not impeded despite the presence of the drug [15]. Another tactic is to isolate the drug, by methods 
such as vesicles or biofilm capture, so that it is spatially separated from its target and cannot affect it 
[15]. A final mechanism is present for drugs that require metabolization to become active. In this 
instance, the process that converts the pro-drug to the active drug becomes less efficient or is lost 
altogether, thus leaving the drug in its non-active state [15]. All these mechanisms prove to be effective 
strategies for increasing an organism’s resistance to antifungal drugs. 
For clarification, resistance does not necessarily mean that a drug will unsuccessfully treat an 
organism. The term describes when the level of the drug that a particular strain requires to achieve 
inhibition of growth is higher than what is considered typical for the species [15]. These increased 
dosages may lead to increased host toxicity and further complicate the patient’s health-state and thus 
can prevent their effective usage. This is problematic because when a healthcare provider detects a 
pathogen causing disease in an individual, the provider will prescribe a dose that will inhibit a standard 
strain of the organism. When the fungal organisms are resistance to these drugs, they can still be used, 
but the dosage must be increased to achieve efficacy [15]. Hence, the dosage prescribed may be too low 
and greatly decrease the likelihood of a positive clinical outcome.  
Candida Species 
 
Candida are a genus of yeast in the division Ascomycota within the same family as 
Saccharomyces cerevisiae or common brewer’s yeast [21]. These species are commonly human 
commensals and can be opportunistic pathogens that account for a large portion of nosocomial, or 
hospital-acquired, infections [22]. Candidemia, or blood infection by Candida spp., is a much more 
serious instance of candida infection, with Candida albicans historically being the major cause [22]. 
Candida albicans displays an exceptional functional plasticity thanks to its many morphotypes [20]. 
Thanks to this functional plasticity, Candida albicans can colonize many areas of the body [20]. Two of its 
morphotypes, the yeast form and the hyphal form, are believed to be required for its pathogenicity. 
Studies examining mutants lacking either morphotype found them to be avirulent [23, 24]. In addition, 
biofilm formation and the secretion of hydrolytic enzymes are crucial to the pathogenesis of C. albicans 
[25]. While C. albicans has claimed many lives over the years, it is successfully treated in many cases and 
rarely displays a significant number of drug-resistant strains. The greatest resistance appears against 
flucytosine, where only 3% of all strains where reported resistant [26]. In recent years, however, there 
has been an increase in the number of other Candida species causing candidemia, such as Candida 
glabrata, Candida parapsilosis and Candida tropicalis [27]. The Center for Disease Control and 
Prevention (CDC) currently offers a panel of drug-resistant isolates for each of these species, known as 
the drug-resistant Candida panel (Appendix I) [28]. Many of these species are innately resistant to some 
of the antifungal drugs that are normally effective at combatting candidemia [18, 29]. The treatment of 
fungal infections with antifungal drugs has placed selective pressure that may be contributing to the rise 
in incidence of infection by drug-resistant species of yeast [18]. When C. albicans is successfully 
eliminated with treatment and the immunocompromised host remains in a vulnerable state, other 
Candida species often fill the void, leading to reinfection. This problem is further compounded by the 
appearance of acquired antifungal drug resistance in both C. albicans and other Candida species [30]. 
One study reported between 20% and 25% of C. albicans isolated from two hospitals were resistant to at 
least one antifungal, and of these, 42% and 64% were resistant to more than one antifungal, 
respectively [30]. This resistance included azoles, echinocandins, polyenes, and flucytosine. [29]. The 
above scenario illustrates another important point. Even though only a small percentage of C. albicans 
isolates are resistant, those strains tend to be concentrated in places like hospitals. This is likely a result 
of the high levels of antifungal drugs in use selecting for resistant organisms and the high density of 
vulnerable individuals.  
 Of these other Candida species, infection by Candida glabrata is the most prevalent [25]. This 
organism is interesting due to its unique genetic state when compared to many other Candida species. 
C. glabrata is well-known to be fastidious, having lost many of the genes required to utilize a wide range 
of substrates [25]. In addition to this, the organism appears to have undergone amplification of genes 
specific to its ability to act as a pathogen and survive inside a host, such as those related to cell adhesion 
[25]. Candida tropicalis is another common cause of candidemia, especially in tropical climates. This 
species shows many of the same morphotypes as Candida albicans, although their exact role in its 
virulence is less well understood [25]. However, one study does show that C. tropicalis can only 
effectively colonize the oral surface in its hyphal form [31]. Closely related to C. tropicalis, Candida 
parapsilosis doesn’t display the same levels of morphotype variability as C. tropicalis or C. albicans, but it 
is still virulent in vulnerable hosts. It does still manifest a hyphal form, although this is not required for 
invasion of the oral epithelium [31]. C. parapsilosis relies heavily on hydrolytic enzymes and biofilm 
formation to successfully cause disease in its host [25].  
Candida auris 
 
One such organism that exemplifies the issue of emerging drug-resistant fungal pathogens is 
Candida auris. It was originally isolated from the inner ear of a patient at a Japanese hospital in 2009 
[32]. Since its initial isolation, it has becoming quite well known as a new “super bug”. Several unique 
strains from four geographically distinct clades have been identified in many clinical cases worldwide 
(Table 2) [33]. These clades are purported to have 
emerged simultaneously and their identity has been 
confirmed by whole genome sequencing which has 
identified thousands of single nucleotide 
polymorphisms [33]. The Center for Disease Control and 
Prevention (CDC) currently offers an isolate panel for 
testing of C. auris, that contains strains from all four 
clades from different parts of the world as well as 
several related species (Appendix 1). The type strain from the original isolation is isolate number 0381 
and is the only member of its clade on the panel. In most cases, the organism is found causing 
nosocomial candidemia that is often lethal [34]. Recent media attention is causing a rapid increase in 
attention for the organism, but there is a serious lack of information due to the recent emergence as a 
pathogen. Three traits of this organism are currently thought to be responsible for its lethality and rapid 
spread. These are its ability to persist, its tendency to be misidentified and the prevalence of drug-
resistant strains. 
Emergence and Persistence 
 
Candida auris is becoming well known for its ability to persist in conditions where related yeasts 
cannot survive. The original description of Candida auris shows that the organism can thrive in 
temperatures as high as 40°C, where most other species grow well only at lower temperatures [32]. A 
recent study suggests that this tolerance may be related to increasing global temperatures [35]. The 
author suggests that the organism originated as a plant saprophyte until its thermal tolerance reached 
levels compatible with mammalian and avian body temperatures. The author also offers a potential 
Isolate # Clade
0381 East Asia, Clade II
0382 South Asia, Clade I
0383 Africa, Clade III
0384 Africa, Clade III
0385 South America, Clade IV
0386 South America, Clade IV
0387 South Asia, Clade I
0388 South Asia, Clade I
0389 South Asia, Clade I
Table 2: C. auris  isolates by clade.
transmission from wetland birds to rural humans and then to urban humans (Figure 3) [35]. Another 
claims that C. auris remains viable for as long as 14 days on soiled healthcare surfaces [36]. The same 
study reports enzymatic activity for C. auris persisted for as long as 28 days post-inoculation [36]. The 
persistence of this organism is enhanced by its transmissibility from surface to host and back. 
Examinations of several early hospital outbreaks detected C. auris colonization a variety of surfaces in 
contact with patients, including medical instruments, bedsheets and several others [37]. A logical step to 
preventing its spread is to follow strict disinfection protocols, which are still in development. However, 
this is complicated by the yeast’s apparently high tolerance to commonly used disinfectants, including 
the ubiquitously used ethanol [38]. To make matters worse, the Environmental Protection Agency (EPA) 
has only recently established guidelines for testing potential disinfectants with C. auris, and the Center 
for Disease Control and Prevention (CDC) has suggested the use of chemicals approved for use with the 
endospore-producing bacterium Clostridium difficile to eliminate C. auris from surfaces [39]. 
 





The second factor that makes Candida auris so threatening is that it is frequently misdiagnosed 
by commonly used diagnostic platforms (Table 3). Candida auris has a general appearance like that of 
many other yeasts when examined on basic growth mediums and under a microscope (Figure 2 and 
Figure 3) [40, 41]. One interesting morphological characteristic of the organism is that it has yet to be 
observed forming hyphae or pseudohyphae [42]. Thus, more sophisticated identification methods are 
required identify Candida auris. The majority of these diagnostic methods identify an organism based on 
its ability to grow using certain substrates or by the chemical reactions that take place as it does so. An 
example of the latter case is CHROMagar Candida. This growth medium-based diagnostic test is able to 
differentially identify many common Candida species based on a color change caused by the organism’s 
Figure 2: Microscopic comparison of Candida albicans (A) and Candida auris isolates 0385 (B), 0390 
(C) and 0382 (D); adapted from [41]. 
Figure 3: Candia auris on CHROMAgar. The appearances of several Candida species on CHROMagar are 
shown in the photograph to the right [43].  On the left is Candida auris on CHROMagar, which 
resembles Candida glabrata [42]. 
enzymatic activity (Figure 3) [43]. When attempting to identify Candida auris on CHROMagar Candida, 
the organism bears a color very similar to Candida glabrata and can easily be misidentified (Figure 3) 
[42].  
The concept of identification by substrate utilization has been expanded by several 
biotechnology companies, such as Biolog and BioMérieux. These companies have developed tests that 
can identify a species by cross-referencing its assimilation pattern of various substrates with a database 
comprised of the typical pattern for most isolates of the organism. Because C. auris is a novel pathogen, 
it has yet to be added to many of these databases, including the aforementioned Biolog database. The 
diagnosis in these and other platforms also presents as a related species in most cases (Table 1) [34]. 
One notable exception occurs when using the MALDI Biotyper. On this platform, Candida auris is 
identified as one of two bacterial species. This is a serious error, because a prescribing clinician would 
prescribe antibacterial drugs that would have no effect on the fungal pathogen.  
Table 3: Misdiagnosis of Candida auris using different identification platforms. 
 




API Candida Candida famata 
























Adapted from [34,42] 
Even when diagnosed as a related species, the treatment process is complicated due to 
differences in treatment procedures between the related species and the likelihood of a positive clinical 
outcome is decreased. Fortunately, new methods of identification that correctly identify isolates as C. 
auris are being developed and validated. The most effective methods utilize quantitative polymerase 
chain reaction (qPCR) to detect representative DNA sequences in the ribosomal RNA and internal 
transcribed spacer regions [44, 45]. These methods can provide a rapid identification and, with the right 
primers, can diagnose other Candida species as well. However, qPCR is a specialized method that 
requires training and equipment that increases the cost of identification. The specialized nature of this 
method presents issues in resource-deficient communities where the organism often flourishes. Thus, 
the gold standard for identifying organisms such as Candida auris will likely remain an approach using 
culture-based media. Through the use of specialized media and occasionally a few simple biochemical 
tests, an organism can be identified with low cost. However, the examination of the metabolic 
capabilities of C. auris to assimilate a variety of compounds and how this compares to related species is 
needed to address a major knowledge gap about the basic properties of this little-understood organism 
and pave the way to produce diagnostic and selective media. The species most closely related to 
Candida auris are Candida haemulonii, Candida duobushaemulonii, and Candida lusitaniae, none of 
which are frequent cause of disease [46]. A simple phylogenetic tree generated using the Taxonomy 
Browser and Tree Viewer of the National 
Center for Biotechnology Information’s 
website displays the taxonomic 
relationship between the isolates of both 
the Candida auris and the drug-resistant 
Candida panels (Figure 4) [47, 48]. 
 
 
Figure 4: Simple phylogenetic tree 
showing the relationship of the 
organisms from the CDC Candida 
auris and drug-resistant Candida 
panels; created using [47, 48]. 
Resistance to Antifungal Drugs 
 
The third trait of Candida auris that causes concern is its propensity to be drug resistant.  Most 
strains are resistant to at least one antifungal drug, usually fluconazole [49]. Many strains display multi-
drug resistance, and some have been found to be resistant to all three major classes of antifungal agents 
[49]. This trait is not isolated to one geographic region. The Candida auris panel mentioned previously 
contains isolates of each clade resistant to at least one class of antifungal [28]. Much uncertainty exists 
about the origin, spread, and epidemiology of C. auris, especially considering that the current opinion is 
that the separate clades emerged as pathogens simultaneously [33]. Regardless of the source, the 
production of new and effective treatment methods is critical to control this organism. 
Methylene Blue 
 
As part of the race towards effective methods for control of C. auris, assessing viability of cell 
cultures in a timely fashion is important. A stain that differentiates viable cells would provide a tool to 
rapidly assess the load of viable cells on those surfaces. This would extend to both persistence of the 
cells in an untreated environment and surface disinfection testing. Currently, viability assessments are 
made using the serial dilution and plate count methods. While these methods are effective at 
determining viability, it is time and resource intensive. Due to incubation times, viability based on plate 
counts cannot be determined in less than 48 hours. The use of a hemocytometer allows for quick and 
accurate estimation of total cell count, but without additional tools, it is impossible to differentiate 
between viable and nonviable cells. In the field of brewing, methylene blue staining is used with 
hemocytometer counts to quantify the percentage of viable Saccharomyces cerevisiae and other 
organisms of an inoculum source for adjusting to appropriate inoculum [50]. In metabolically active 
cells, the stain is metabolized to a colorless compound and the cells retain their hyaline 
(unstained)appearance under light microscopy. In metabolically inactive cells, the stain remains, and the 
cells appear blue. It is reasonable to assume that this technique could be extended to the pathogenic C. 
auris, possibly allowing a combination of rapid cell counts and viability determination. 
Essential Oils 
 Plants have long been utilized to treat a variety of diseases, infectious or otherwise. As plant 
cells are fixed in place and thus circulating immune cells are not an option for protection from 
pathogens, other defense mechanisms must be present to combat pathogens [51]. One of these 
mechanisms is the production of antimicrobial compounds, many of which are of low molecular weight, 
volatile and bear a pronounced odor [51]. The volatile nature and odor have drawn human interest in 
extracting these compounds for use as air fresheners and other scented products. Essential oils are 
produced by separating these volatile compounds from plant matter primarily by steam distillation, 
although extraction by cold pressing is sometimes used. After the liquid condenses, the water insoluble 
compounds separate and are collected. A review of the chemistry and biological activities of essential 
oils is published elsewhere [52]. 
Antimicrobial Activity 
 
Essential oils are also a combination of some of the chemical weaponry utilized by plants. The 
volatile compounds easily diffuse from the damaged plant tissue and bear a strong odor, many of which 
deter predatory animals from consuming the plant [53]. The aversion to the smell is actually a response 
that organisms have developed because the odor indicates the presence of compounds that are toxic to 
other organisms [54]. The toxic properties of these chemicals extend beyond animal predators. Many of 
these oils also have antimicrobial properties against viruses, bacteria, and fungi [55, 56, 57, 58]. This 
makes the oils an attractive and mostly untapped reservoir for antimicrobial treatments. This interest is 
enhanced as they are also markedly less expensive than clinical drugs for the end-user. One issue in their 
application as therapeutic medicine is in their indiscriminate toxicity [59]. Just as they can kill microbes, 
they can prove damaging to human cells in elevated doses. Thus, many are considered “hot” oils in that 
they must be diluted to avoid reactions and cell damage when used topically [59]. Another issue is that 
many factors, such as plant growth conditions and manufacturing procedures, can alter the balance of 
the various chemicals present in the oils and make it more difficult to standardize them [52]. However, 
there is yet little evidence that these differences significantly impact the effectiveness. Other factors 
also increase the value of these oils as potential treatment options. Due to the volatile nature of 
essential oils, they are often used in aromatherapy and some reports claim that they retain their 
antimicrobial properties when volatilized [58, 60].  
Synergism 
 
Combination treatment is not a new concept. Drugs have been used in combination to treat 
difficult infections for almost as long as drug-resistance has been a problem [61]. A classic example is 
using augmentin to treat penicillin-resistant bacteria [62]. Some of these bacteria produce an enzyme 
that breaks down the active region of the beta-lactam antibiotics, to which penicillin and cephalosporin 
belong. Augmentin contains penicillin and a salt of clavulanic acid. The acid salt is present because it 
competitively inhibits the beta-lactamase (enzyme conferring resistance) and allows penicillin to 
function. An example of combination treatment used on a fungal pathogen is the combination of 
amphotericin B and flucytosine against the yeast pathogen Cryptococcus neoformans. One study shows 
an enhanced killing of all isolates tested when the two drugs are used in combination [63]. A 
comprehensive review describing combination therapies in use and guidelines for the validation and use 
of combination treatments is published elsewhere [61]. Recent evidence also suggests that essential oils 
can function in a synergistic association with antimicrobial drugs, including antifungals [57, 64, 65]. 
Synergism is the name given to the property of some chemicals to enhance the effect of another drug 
when used in combination. This is different than additivity, where the effect is the sum of its parts. In 
synergism, the effects are actually enhanced. For example, assume two hypothetical drugs each 
required two grams per milliliter to elicit a three-log reduction of a pathogen when used alone. If these 
two drugs were additive, the same three-log reduction can be achieved using a mixture containing one 
gram, or half the dose of each, per milliliter of each. If the two drugs were synergistic, on the other 
hand, the same mixture might elicit a 4-log reduction of the pathogen instead. This is a desirable 
outcome because, as previously mentioned, antifungal drugs are expensive and can cause side effects 
that can be severe at the elevated doses needed to treat infections by resistant organisms. This 
phenomenon can restore the utility of antibiotics that have mostly been abandoned due to the 
widespread resistance to them. Given the current situation where antibiotics are being rendered 
increasingly ineffective due to drug-resistant organisms, the benefits of exploring essential oils are at 
least two-fold. For one, they may provide alternative treatment options for these resistant pathogens. 
Secondly, they can restore and enhance the utility of other treatments that have been benched due to 
ineffectiveness.  
There are problems when evaluating combinations for synergistic associations, however. First, 
chemicals don’t always complement each other. Just as some combinations display synergism, others 
will display indifference or even act against each other. In the case of indifference, the treatment will 
require the full dose of both chemicals, which, if used, can present the side effects for both chemicals. In 
the latter case, which is known as antagonism, the drugs inhibit each other, causing an increased overall 
dose required to treat the infection [61]. The second issue is the evaluation of the interaction between 
the drugs. Several methods are currently used, and the description and interpretation of the results can 
differ between each [66]. Thus, a clear description of the method used to acquire and interpret results is 
mandatory so that other researchers can build upon the data generated. The third issue is that 
combinations sometimes vary in effectiveness based on the timing of the administration of each drug. 
An example is the combination of amphotericin B and fluconazole [61]. When fluconazole is introduced 
first, it depletes the ergosterol targets of amphotericin B and thus decreases the overall effectiveness of 
the combination. When amphotericin B is added first, however, it creates pores in the cellular envelope 
that allows the later-added fluconazole greater access to its targets. The final issue is present for all drug 
treatments but is still important to consider. Even though a combination may display a certain 
interaction and effectiveness in vitro, further investigation is needed to determine if these properties 
will be retained in vivo. 
Research Objectives 
 
 The investigations conducted here are multifaceted and sought to address several of the issues 
mentioned above. All of the work focused on a core group of isolates. All but one of these isolates were 
obtained from the CDC, described in Appendix I. The other isolate was a strain of Candida albicans that 
was obtained from the United States Department of Agriculture’s Northern Regional Research 
Laboratory (NRRL) collection. This isolate’s details are also listed in Appendix I.  
This study was organized into several experimental objectives. The first objective of this study 
was to streamline a process for the preparation of a standardized inoculum. Second, the work sought to 
test the efficacy of methylene blue as a viability staining agent on C. auris. Third, the basic metabolic 
capability of C. auris to assimilate various chemicals as a sole source of carbon or nitrogen was 
examined. Fourth, C. auris was examined for a distinct pattern of fermentation and assimilation using 
the appropriate Biolog product. Fifth, the antimicrobial activity of select essential oils against C. auris 
was examined. Sixth, the ability of these essential oils to display antimicrobial activity in vapor phase 
was briefly explored. Seventh, the interaction between the most effective oils and select antifungal 
drugs was examined using C. auris as well as Candida lusitaniae and Saccharomyces cerevisiae. The 
overall goal was to increase and understanding of the novel fungal pathogen and produce data and 




Culture preparation and maintenance 
 
  Two panels of drug resistant Candida species were acquired from the CDC (Appendix I). The first 
was the Drug Resistant Candida Panel (species other than C. albicans) and the second was the Candida 
auris Panel, consisting of 32 and 20 strains, respectively. The isolates were received as glycerol stocks, 
which were inoculated into malt extract broth (MEB) and onto malt extract agar (MEA). All cultures were 
incubated at 37°C for two days. Samples from colonies grown on MEA, of each organism, were used to 
create stocks in 30% glycerol for long-term storage at -80°C. The MEA plates were retained for future 
use and preserved by wrapping in parafilm and refrigerating at 4°C. New MEA plates were inoculated at 
least once a month by quadrant-streaking from a colony of an older plate. After a fifth-generation plate 
was made, a fresh series was created from the glycerol stocks, which was performed to maintain the 
isolate’s wild-type characteristics. 
Absorbance-Population Determination 
 
 To allow for rapid determination of population size using optical density at 600 nm (OD600), a 
standard curve and function of these two values was constructed for each species present in either 
panel. Isolates 0385, 0389, 0391, 0393, 0396, 0397, 0398, 0399, 0325, 0344, 0345, and NRRL-Y12983 
were chosen to represent one isolate of each species. Two isolates of Candida auris were chosen, 
however, to verify that that the standard curve would remain consistent between isolates of the same 
species. To construct the curves, an overnight culture of each isolate was grown in MEB at 30°C with 
shaking at 250 RPM. The following day, the cultures were diluted to a population that appeared 
countable using a hemocytometer. This dilution was considered the starting population. Further 
dilutions were created to yield 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90% of the starting 
population. These nine dilutions and the starting population encompassed the samples tested. Triplicate 
aliquots of each of these samples were transferred to cuvettes and the OD600 was measured for each 
using the spectrophotometer. Then, triplicate aliquots of 10 μL of each dilution were added to the 
hemocytometer and counted under the light microscope. The mean of the triplicate of both the OD600 
values and the cells counts was calculated and the OD600 was plotted against the cell counts for each 
organism using Excel™. The equation for the trendline and the R2 were then generated using the same 
software. 
Working Stock Preparation 
 
 To obtain standardized starting populations with a more rapid preparation for all experiments, 
glycerol working stock were prepared at standardized population sizes. For each isolate used, an 
overnight culture was grown at 30°C with shaking. The following day, the population was standardized 
to 1.0 – 2.0 x 106 cells mL-1 based on the standard curve previously determined. Then, 1.0 mL of the 
culture was mixed with an equal volume of 60% glycerol to yield a 2.0 ml working stock in 30% glycerol. 
These were stored at -80°C and were discarded if not used within a month to ensure viability was 
retained.  
Methylene Blue Validation 
 
C. auris (AR0389) of the CDC Candida auris panel was used as the challenge organism. S. 
cerevisiae (AR0399) from the same panel was used as the control organism. Overnight cultures of S. 
cerevisiae and C. auris were grown at 37°C with 250 RPM shaking in MEB. One half of the volume, or 10 
mL, of each culture was placed in boiling water for 10 minutes while the other half was held at room 
temperature to generate four samples. An aliquot of 100 μL from each sample was mixed with an equal 
volume of 0.02% methylene blue and incubated for 5 minutes at room temperature. Triplicate aliquots 
of the stained samples were loaded into a hemocytometer, and each was microscopically observed and 
counted to determine the percentage of viable cells. Viable cells were identified by the retention of their 
normal hyaline character. To then validate the viable counts estimated by the hemocytometer with 
methylene blue, the experiment was repeated with the addition of the following step. Samples from the 
treatment groups were diluted to less than 103 cells mL-1, viable or otherwise, using the hemocytometer 
counts to determine the relevant dilution factor. From the diluted samples, 0.1 ml of each were spread 
across the surface of separate MEA plates in triplicate and incubated for 48 hours at 37°C. The 
hemocytometer and plate counts were compared to determine the accuracy of the staining method to 
quantify viable cells. A two-tailed Student’s t-test assuming unequal variance was used to determine if 




Carbon and Nitrogen Source Testing 
 
Carbon Source Utilization 
 
To determine the capability of C. auris and the related Candida spp. to utilize various substrates 
as their sole carbon source, growth experiments were performed in minimal media containing only the 
tested substrate as a carbon source. The base media was yeast nitrogen base without amino acids (YNB). 
This was supplemented with the following carbon sources separately at a concentration of 2% by 
volume: D-glucose, D-galactose, L-arabinose, D-xylose, maltose, lactose, sucrose, raffinose, 
maltodextrin, glycerol, dulcitol, mannitol, and dodecane (Table 4). Dodecane was adjusted to 1% by 
volume due to the compound containing nearly twice the carbon per unit weight, whereas the others 
had the same levels of carbon by weight. The isolates used encompassed the entire Candida auris panel 
and included isolates 0325, 0333, 0340, 0344 and 0345 for the Drug-Resistant Candida panel as well as 
the NRRL Y-12983 isolate of Candida albicans. A working stock of each isolate used was obtained from 
the -80°C freezer, thawed and centrifuged. The excess glycerol solution was then decanted, and the 
organism was washed and resuspended in 1.0 mL of conidia harvesting solution (CHS). Each well of a 96-
well plate was filled with 190 μL of YNB supplemented with one of the carbon sources and was 
inoculated with 10 μL (approximately 104 cells) of the prepared working stock culture. Negative controls 
for each carbon source using CHS in place of inoculum were included. Each carbon source was tested in 
triplicate for each isolate. The plates were sealed using parafilm to prevent evaporation and incubated 
at 30°C. At 0, 24, 48 and 72 hours, the plate was agitated to homogenize the contents of each well and 
the OD600 of each well was read.  
Nitrogen Source Utilization 
 
A modified carbon-source utilization method was used to determine the capability of utilizing 
sole nitrogen sources. The base media used was yeast carbon base (YCB) instead of yeast nitrogen base, 
supplemented with one of the following nitrogen sources: ammonium acetate, sodium nitrate, sodium 
nitrite, urea, L-arginine, L-valine, glycine, L-proline, D-valine, uracil, thymine, thiamin or pyridoxin. These 
were standardized to contain an equivalent amount of nitrogen as 0.01% ammonium acetate (Table 4). 
Growth parameters and procedures otherwise followed the Carbon Source Utilization protocol 
described above. 
Table 4: Carbon and Nitrogen Sources. 
Carbon Source Percent (v/v) Nitrogen Source Percent (v/v) 
D-glucose 2% ammonium acetate 0.01% 
D-galactose 2% sodium nitrate 0.01% 
maltose 2% sodium nitrite 0.01% 
sucrose 2% L-valine 0.004% 
lactose 2% glycine 0.006% 
L-arabinose 2% L-proline 0.02% 
D-raffinose 2% L-arginine 0.01% 
D-xylose 2% D-valine 0.02% 
glycerol 2% urea 0.02% 
mannitol 2% thiamin 0.01% 
maltodextrin 2% pyridoxin 0.01% 
dodecane 1% thymine 0.01% 
dulcitol 2% uracil 0.03% 
 
Substrate Utilization using Biolog YT Plates 
 
 The Biolog YT plate was used to examine how C. auris was identified by the Biolog system and 
how the organism utilized the substrates contained by the plate (Appendix II). The first objective was to 
determine the accuracy of the system in identifying known organisms. To do this, overnight cultures of 
Candia auris (AR0385), Candida lustaniae (AR0398) and Saccharomyces cerevisiae (AR0399) were grown 
on Biolog Universal Yeast (BUY) Agar. The following day, the colonies from the plates were suspended in 
sterile deionized water and standardized to within 2% of the transmittance of the Biolog YT standard 
using the Biolog turbidimeter. One hundred μL of one culture was transferred to each well of the YT 
plate. Triplicate plates were set up for each organism. These were incubated for 48 hours at 30°C. 
Following incubation, the plates were read using the Biolog Microstation and examined using the Biolog 
Microlog software. The remaining isolates of Candida auris were each tested once using the procedure 
above. 
 
Antifungal properties of Essential Oils 
 
Antifungal Activity Testing 
 
 The antifungal activity of several essential oils was tested using a modified microdilution 
method. The selected essential oils are listed in Appendix III with the maximum concentration safe for 
dermal use, where available [59]. Two isolates of Candida auris (AR0381 and AR0385) were used, as well 
as one isolate each of C. lusitaniae (AR0388) and S. cerevisiae (AR0399). The base media was yeast 
nitrogen base supplemented with 2% glucose (YNBG). 380 μL of YNBG supplemented with 1% of the 
tested essential oil was added to the first well of a column on a 96-well plate. The remaining wells of the 
column were filled with 190 μL of YNBG with 1% dimethyl sulfoxide (DMSO). Microdilutions were 
performed by transferring 190 μL of the top well’s contents to the second well and mixing. One hundred 
ninety μL of the second was transferred to the third well and mixed. This was repeated for the entire 
column of eight wells, with 190 μL of the contents of the last well being discarded to ensure an equal 
volume in each. This process replaced the diluted essential oil with DMSO to ensure an equal 
concentration of media was present in each well. After the microdilutions were prepared, each well was 
inoculated with 10 μL of a thawed working stock, for a starting population size of 1.0 – 2.0 x 104 
cells/well. The final working volume of each well was 200 μL. The plates were sealed using breathable 
cover films and incubated for 72 hours at 30oC. Following incubation, the plates were agitated to 
homogenize the contents of each well and the OD600 was read using a plate reader. Each microdilution 
series was performed in triplicate. The mean was taken for the triplicate of each concentration. 
Complete inhibition was determined by a mean OD600 value of less than 0.5. The MIC was assigned to 
the minimum concentration that inhibited the growth of the starting population.  
The contents of the inhibited wells were then transferred to 1.0 mL of Letheen neutralizing 
broth. Letheen broth functions both to neutralize the antimicrobial activity of the essential oil and as a 
growth medium. The broth cultures were then incubated for 72 hours at 30°C with shaking. Following 
incubation, the tubes were observed for any visual signs of growth. The MFC was determined as the 
minimum concentration that displayed no growth at this phase. Negative controls were included for the 
essential oil, DMSO, YNBG and the Letheen broth. A positive control containing DMSO and Letheen 
broth was included.  
 
Antifungal Activity of Essential Oils in Vapor-Phase 
 
 Each essential oil was tested for antifungal activity in vapor-phase in a sealed airspace. Working 
stocks of C. auris (0385) were diluted to yield population sizes of 50-100 cells per 10 μL. Then, 10 μL of 
this culture was transferred to four 60 mm Petri dishes containing MEA and spread over the agar. Three 
of these plates were then placed with the lids removed in an empty 150 mm Petri dish. A small cup 
made of aluminum foil was placed at the center of the large Petri dish and filled with 100 μL of the 
tested essential oil. The lid of the 150 mm Petri dish was immediately replaced, and the plate was sealed 
with parafilm to create an enclosed airspace. The fourth 60 mm plate was independently sealed with 
parafilm and used as a viability control. All plates were incubated for 72 hours at 30°C. Following 
incubation, the 60mm plates were observed for growth and inhibition was determined when no growth 
was observed. Lids were then replaced on the inhibited plates, sealed with parafilm and returned to 
incubation for an additional 72 hours. Following the second incubation period, the plates were again 
checked for growth. Lethality was determined when the plates showed no obvious signs of growth at 
this phase. This experiment was then repeated using 10 μL of the essential oils that displayed fungicidal 
activity at 100 μL and using 1 μL of the essential oil diluted in 99 μL of DMSO for the oils that displayed 
fungicidal activity at 10 μL. 
Synergism Testing 
 
 A modified checkerboard method was used to examine the interaction between the essential oils 
displaying the lowest MIC’s and select antifungal drugs. The oils tested were lemongrass, clove bud and 
cinnamon bark. The antifungals used were amphotericin B, flucytosine, fluconazole, and micafungin. One 
strain each of C. auris (0381), C. lusitaniae (0398), and S. cerevisiae (AR0399) was used as challenge 
organisms. Stock solutions of the antifungals were prepared by dissolving the drug in pure DMSO to yield 
concentrations not exceeding the manufacturer’s recommended solubility limit. Working solutions were 
prepared for each organism by diluting the stock solutions in sterile deionized water to produce 
concentrations equal to 320 times the published MIC for the organism. Then, a separate solution was 
mixed using YNBG with 1% of a combination of DMSO and the tested essential oil.  
The volume of essential oil used was calculated to yield a final solution containing 16 times the 
previously determined MIC for the organism. Three hundred sixty uL of this solution was added to the 
first well of the first column on the 96-well plate. One hundred ninety μL was added to the remaining 
wells of the column and to the first well of column 9. The remaining solution containing YNBG, essential 
oil, and DMSO was then diluted with an equal volume of YNBG plus 1% DMSO to yield a new solution with 
half the concentration of essential oil. 360 μL of this solution was added to the first well of the second 
column and 190 μL was added the remaining wells of the column and the second well of column nine. The 
process of diluting the essential oil mixture and adding it to the plate was repeated for the next six 
columns of the 96-well plate. Three hundred sixty  μL of the YNBG plus 1% DMSO was added to the top 
well of the tenth column and 190 μL was added to the remaining wells of the column.  
After the essential oil microdilutions were performed, 20 μL of the antifungal working solution 
was added to the top well of each column, except for columns nine, eleven and twelve. Then, 190 μL of 
the contents of the top well of the first column was transferred to the second well and mixed. 190 μL of 
the second well was transferred to the third and mixed. This was continued for the remainder of the wells 
in the column, with 190 μL of the contents of the last well being discarded to ensure an equal volume was 
present in all wells. These microdilutions were repeated for columns two through eight, as well as column 
ten. The final plate contained combinations of every tested concentration of essential oil and antifungal 
as well as each concentration of essential oil and antifungal in isolation in columns nine and ten, 
respectively (Table 5).  
After the antifungal microdilutions were complete, 10 μL containing approximately 1.0 - 2.0 x 104 
cells of the working stock culture was added to each test well. Triplicate plates were sealed using 
breathable cover films and incubated for 72 hours at 30°C. Following incubation, the plates were agitated 
to homogenize the contents of each well and the OD600 was observed and recorded for each well. The 
mean of the triplicate results was calculated, and complete inhibition was determined when the mean of 
the OD600 readings for a particular combination was less than 0.5. The fractional inhibitory concentration 
index (FICI) of the checkerboard assays was calculated from the fraction inhibitory concentrations (FICs) 
as shown in Table 6 [64]. The test well used to determine the MIC in combination was the one located 
most centrally along the inhibition interface. The interpretation of the interaction is also as previously 
described (Table 6) [67]. 
  
Table 5: General layout of the checkerboard plates. EO: essential oil MIC, AF: antifungal MIC, DMSO: 
dimethyl sulfoxide. 
16xEO       
16xAF 
8xEO              
16xAF 
4xEO              
16xAF 
2xEO              
16xAF 
1xEO              
16xAF 
0.5xEO              
16xAF 
0.25xEO              
16xAF 
0.125xEO              
16xAF 






16xEO       
8xAF 
8xEO              
8xAF 
4xEO              
8xAF 
2xEO              
8xAF 
1xEO              
8xAF 
0.5xEO              
8xAF 
0.25xEO              
8xAF 
0.125xEO              
8xAF 






16xEO       
4xAF 
8xEO              
4xAF 
4xEO              
4xAF 
2xEO              
4xAF 
1xEO              
4xAF 
0.5xEO              
4xAF 
0.25xEO              
4xAF 
0.125xEO              
4xAF 






16xEO       
2xAF 
8xEO              
2xAF 
4xEO              
2xAF 
2xEO              
2xAF 
1xEO              
2xAF 
0.5xEO              
2xAF 
0.25xEO              
2xAF 




16xEO       
1xAF 
8xEO              
1xAF 
4xEO              
1xAF 
2xEO              
1xAF 
1xEO              
1xAF 
0.5xEO              
1xAF 
0.25xEO              
1xAF 




16xEO       
0.5xAF 
8xEO              
0.5xAF 
4xEO              
0.5xAF 
2xEO              
0.5xAF 
1xEO              
0.5xAF 
0.5xEO              
0.5xAF 
0.25xEO              
0.5xAF 




16xEO       
0.25xAF 
8xEO              
0.25xAF 
4xEO              
0.25xAF 
2xEO              
0.25xAF 
1xEO              
0.25xAF 
0.5xEO              
0.25xAF 
0.25xEO              
0.25xAF 




16xEO       
0.125xAF 
8xEO              
0.125xAF 
4xEO              
0.125xAF 
2xEO              
0.125xAF 
1xEO              
0.125xAF 
0.5xEO              
0.125xAF 
0.25xEO              
0.125xAF 






Table 6: Interpretation of fractional inhibitory concentration index (FICI).  
FICI= FIC of Oil* + FIC of Antifungal** 
FICI ≤ 0.5 Synergistic 
0.5 < FICI ≤ 1.0 Additive 
1.0 < FICI ≤ 4.0 Indifferent 
FICI > 4.0 Antagonistic 
 
*FIC of Oil =             MIC of Oil in Combination 
 MIC of Oil Alone 
  
**FIC of Antifungal = MIC of Antifungal in Combination 
 MIC of Antifungal Alone 







 In all cases, the absorbance at 600 nm correlated linearly with the populations counted using 
the hemocytometer (Figures 5-16). The functions all appear as expected, with a slope between 1.0 – 8.0 
x 108 (Table 7). Some variation in the correlation between OD600 and population size exists between the 
different species of yeasts. The most pronounced is Saccharomyces cerevisiae, which displays a 
substantially lower population at a given absorbance than the other yeasts. In all cases, the functions 
point towards a population in the range of 108 cells mL-1 at an OD600 of 1.0. This similarity is expected of 
related organisms of similar size. 
 
Figure 5. Absorbance at 600 nm to population standard curve for Candida auris AR0385.  































Figure 7: Absorbance at 600 nm to population standard curve for Candida duobushaemulonii AR0391.  
 


























































Figure 9. Absorbance at 600 nm to population standard curve for Kodamaea ohmeri AR0396.  
 



























































Figure 11: Absorbance at 600 nm to population standard curve for Candida lusitaniae AR0398. 
 



























































Figure 13: Absorbance at 600 nm to population standard curve for Candida glabrata AR0325.  
 

























































Figure 15: Absorbance at 600 nm to population standard curve for Candida tropicalis AR0345.  
 






















































Figure 16. Absorbance at 600 nm to population standard curve for Candida albicans NRRL Y-12983.  
 
 
Table 7: Absorbance to population functions. 
Strain Function* R
2 
Candida auris 0385 y = (5 x108)x - 1𝑥106 0.992 
Candida auris 0389 y = (5 x108)x - 8 𝑥106 0.979 
Candida duobushaemulonii 0391 y = (3 x108)x – 6 𝑥105 0.988 
Candida haemulonii 0395 y = (4 x108) x- 5 𝑥106 0.942 
Kodamaea ohmeri 0396 y = (5 x108)x - 1 𝑥107 0.976 
Candida krusei 0397 y = (4 x108)x - 1 𝑥107 0.976 
Candida lusitaniae 0398 y = (2 x108)x - 1 𝑥107 0.984 
Saccharomyces cerevisiae 0399 y = (1 x108)x - 2 𝑥106 0.995 
Candida glabrata 0325 y = (5 x108)x - 1 𝑥107 0.921 
Candida parapsilosis 0344 y = (4 x108x + 3 𝑥104 0.943 
Candida tropicalis 0345 y = (4 x108)x - 1 𝑥106 0.942 
Candida albicans NRRL Y-12983 y = (6 x108)x - 4 𝑥106 0.977 
* y = population, x = absorbance 
 
Methylene Blue Validation 
 
 The boiled samples of both C. auris and S. cerevisiae displayed the typical blue staining in all 
cases, while the non-boiled samples remained hyaline (Figure 17). There was no significant difference in 
























Candida albicans NRRL Y-12983
viability (p=0.99) between the staining and plate count methods (Figure 18). No viability was detected 
from the boiled samples using either method.  
-  
Figure 17:  Hemocytometer grid at 400x magnification with boiled and non-boiled Saccharomyces 
cerevisiae and Candida auris after being stained with methylene blue. S. cerevisiae non-boiled (A), S. 
cerevisiae boiled (B), C. auris non-boiled (C), and C. auris boiled (D). Non-viable cells are stained blue. 




Figure 18: Viability of Candida auris and Saccharomyces cerevisiae using hemocytometer enumeration 
following methylene blue staining and traditional plate counts. Results are the average of triplicate 
counts for each, with the average being displayed above the corresponding bar. Units presented are 
viable cells for hemocytometer counts and colony-forming units for plate counts. 
Substrate Utilization 
 
Carbon Source Assimilation 
 
 Each species displayed a unique pattern of carbon assimilation. (Tables 7, 8 and 9). Negative 
results are indicated by red shading and are determined as an OD600 of less than 0.2, which 
corresponds to a lack of visible growth. Positive results are shaded green and determined as an OD600 
of greater than 0.5, which corresponds with obvious visible growth. Those intermediate in this range are 
colored yellow and identified as weak growth. All isolates did not reach the positive range on several 
carbon sources by 24 hours. Some of these did not reach the needed OD600 until 72 hours. C. auris did 
not assimilate galactose or xylose, while all other species except C. glabrata can assimilate galactose, 
although C. haemulonii only does so weakly. Some substrates showed variable results between isolates 
at 72 hours for C. auris. These were lactose, L-arabinose, and dulcitol. The variability was not isolated by 
clade. C. glabrata only assimilated glucose. Lactose and L-arabinose display some variability among the 





































and is only weakly utilized by C. haemulonii. Dulcitol, dodecane and xylose also display some variability 
between the two isolates of S. cerevisiae. The CHS controls remained negative as expected.
Table 7: Carbon usage profiles of Candida auris and other related species at 24 hours. 
 
    D-glucose D-galactose D-maltose sucrose lactose L-arabinose D-raffinose D-xylose glycerol mannitol maltodextrin dodecane dulcitol 
















  0381  0.495667 0.006111 0.226556 0.390222 0.026111 0.219889 0.329111 0.009667 0.244111 0.187222 0.390333 0.322444 0.155667 
  0382 0.510111 0.000222 0.209111 0.433444 0.105556 0.114778 0.409778 0.003889 0.163 0.203556 0.609667 0.265222 0.181 
  0383 0.059111 0.005778 0.018778 0.037 0.017111 0.013333 0.042 0.002667 0.016667 0.025222 0.062667 0.152778 0.044889 
  0384 0.008556 -0.01489 0.002 0.002778 0.004444 -0.00033 0.009778 0.000444 0.002889 0.015 0.024 0.049222 -0.01144 
  0385 0.009111 0.006222 0.003778 0.008444 0.046444 0.028778 0.002444 0.000889 0.018333 0.003889 0.002333 0.072111 0.009889 
  0386 0.426667 0.003111 0.223556 0.318889 0.092556 0.100556 0.347889 0.027556 0.084111 0.167222 0.346667 0.244444 0.045222 
  0387 0.081778 -0.00878 -0.00778 0 0.001 -0.00833 0.003889 0.001 0.004556 0.003 0.013889 0.196111 0.002667 
  0388 0.068556 -0.00622 0.007111 0.011556 0.006667 0.004111 0.017556 0.002111 0.000222 0.008222 0.051333 0.020889 -0.00244 
  0389 0.056889 0.001889 0.009 0.010444 0.009111 0.007 0.014 0.002 0.008444 0.011444 0.031222 0.031889 -0.00744 














  0391 0.214778 0.259889 0.181111 0.164556 0.041333 0.018667 0.019889 0.003778 0.043 0.132333 0.285556 0.051889 0.041778 
  0392 0.178889 0.017889 0.058444 0.117333 0.029333 0.022667 0.067111 0.002556 0.025889 0.052222 0.100556 0.142444 0.046556 
















  0393 0.248556 0.121 0.027889 0.075222 0.018111 0.018 0.052444 0.037556 0.011333 0.086889 0.182333 0.064556 0.020667 






























































0399 0.588111 0.025222 0.195 0.702444 0.076444 0.034333 0.184556 0.022778 0.030556 0.039 0.626 0.063444 0.032778 
















0325 1.447667 0.003222 0.015444 0.003444 0.004889 0.061556 0.060556 0.001556 0.002 0.003778 0.131333 0.018889 0.012889 













  0344 0.242667 0.141333 0.104222 0.116778 0.071889 0.038556 0.013889 0.023778 0.072889 0.090444 0.191889 0.064222 0.084556 




























    0.707111 0.257111 0.067667 0.181667 0.016667 0.034444 0.776222 0.095111 0.049667 0.140111 0.274889 0.104222 0.029111 




Table 8: Carbon usage profiles of Candida auris and other related species at 48 hours. 
    D-glucose D-galactose D-maltose sucrose lactose L-arabinose D-raffinose D-xylose glycerol mannitol maltodextrin dodecane dulcitol 
















  0381 1.231667 0.019556 0.672778 1.009556 0.055889 0.394778 0.795 0.011333 0.476111 0.610444 0.801 0.406444 0.245556 
  0382 1.458667 -0.00611 1.092778 1.132222 0.381556 0.347778 0.835444 0.006556 0.460667 0.755556 1.265111 0.656556 0.390556 
  0383 1.213473 0.025584 0.657497 0.862131 0.199122 0.223345 0.617092 0.012008 0.276023 0.443771 0.991868 0.305813 0.140592 
  0384 1.170168 0.022885 0.611199 0.816776 0.189484 0.209212 0.587508 0.011694 0.262617 0.417297 0.950324 0.284467 0.129751 
  0385 1.355111 0.034222 0.373556 0.634 0.117 0.177778 0.223 0.002 0.109 0.144333 0.780333 0.115889 0.088111 
  0386 1.223222 0.052333 1.06 1.061222 0.294889 0.353111 0.932556 0.065444 0.418444 0.759556 1.150889 0.374556 0.261444 
  0387 1.153789 0.027289 0.563211 0.746422 0.1764 0.192789 0.544078 0.010389 0.245944 0.400522 0.940244 0.27 0.128177 
  0388 1.131333 0.004111 0.375 0.659444 0.073889 0.069556 0.379333 0.005333 0.102778 0.229222 1.132444 0.164333 0.059222 
  0389 1.266889 -0.00333 0.860556 0.960444 0.403778 0.227778 0.684111 0.003556 0.261222 0.512444 1.025889 0.278222 0.017667 














  0391 1.152778 0.365111 0.735889 0.827333 0.308222 0.101222 0.354222 0.004 0.292556 0.595111 0.742444 0.309333 0.285444 
  0392 1.178444 0.137222 0.430444 0.800667 0.179667 0.150667 0.439667 0.007778 0.214444 0.481778 0.705111 0.356222 0.210667 
















  0393 1.177333 0.202556 0.527667 0.724778 0.172556 0.079556 0.201111 0.560444 0.059333 0.536667 0.665 0.082667 0.108111 






























































0399 1.175778 1.124778 1.034111 1.315778 0.241889 0.190333 0.432333 0.08111 0.08078 0.060667 0.488444 0.077222 0.109667 
















0325 1.442889 0.004111 0.012667 0.007333 0.029778 0.062222 0.104333 0.000222 0.001111 0.003333 0.070667 0.006 0.089889 














  0344 1.033333 0.717778 0.617333 0.720778 0.638778 0.338889 0.05444 0.278333 0.406111 0.548 0.637667 0.325111 0.598222 




























  Y-12983 1.472111 1.013333 0.908222 0.661556 0.05344 0.236556 0.480333 0.612444 0.317222 0.647444 0.929778 0.334667 0.12833 





Table 9: Carbon usage profiles of Candida auris and other related species at 72 hours. 
    D-glucose D-galactose D-maltose sucrose lactose L-arabinose D-raffinose D-xylose glycerol mannitol maltodextrin dodecane dulcitol 
















  0381 1.379444 0.035111 1.019889 1.210333 0.084889 0.542111 0.969667 0.019 0.688444 0.853222 1.036333 0.545667 0.621444 
  0382 1.559778 -0.00144 1.572 1.369 0.690556 0.631 1.111333 0.034333 0.922111 1.080778 1.482222 0.670333 0.500667 
  0383 1.341778 0.11 1.077333 1.142333 0.610444 0.588778 0.955778 0.014222 0.711778 0.960556 1.243889 0.689333 0.223778 
  0384 1.363333 -0.00422 1.084333 1.175 0.593333 0.211 0.943778 0.006111 0.567333 0.760222 1.138 0.749111 0.091 
  0385 1.419444 0.150222 0.948333 0.845222 0.385556 0.497222 0.786778 0.011778 0.355111 0.769667 1.033444 0.294556 0.249778 
  0386 1.512778 0.086889 1.293222 1.184444 0.565667 0.571 1.055333 0.077556 0.816556 1.107556 1.399222 0.653778 0.639222 
  0387 1.3972 0.070912 1.118967 1.128756 0.426589 0.4082 0.931356 0.021556 0.572044 0.877133 1.2417 0.555667 0.285078 
  0388 1.456333 0.068667 1.310556 1.208111 0.223556 0.235556 0.884556 0.007889 0.231556 0.732333 1.315778 0.347222 0.170444 
  0389 1.243 0.024556 1.203667 1.158556 0.804333 0.544222 0.863889 0.042222 0.630444 0.699444 1.029556 0.592667 0.103556 














  0391 1.213111 0.722 0.964444 1.024778 0.635222 0.285444 0.452778 0.030222 0.617222 0.837889 0.842667 0.517111 0.566 
  0392 1.492444 0.781667 1.114444 1.438111 0.785 0.744556 1.100778 0.007111 0.748778 0.801333 0.701444 0.790778 0.75 
















  0393 1.395111 0.447333 0.897667 1.043333 0.439556 0.293222 0.471556 0.837889 0.217444 0.803889 0.834 0.160556 0.326333 






























































0399 1.239667 1.341778 1.190444 1.418333 0.591889 0.300778 0.311889 0.218556 0.13233 0.357778 0.624667 0.148111 0.377222 
















0325 1.111444 0.005333 0.010333 0.042333 0.077333 0.058556 0.166556 0.001333 0.008222 0.021444 0.0567 0.016 0.080556 














  0344 1.125778 0.978333 0.932444 0.970222 0.746444 0.743222 0.11944 0.722778 0.717 0.951111 0.901333 0.738333 0.776333 




























  Y-12983 1.474667 1.307222 1.317556 1.019 0.00367 0.456111 0.793 0.869667 0.533667 0.968889 1.151667 0.450111 0.07889 
a Positive(Green):OD600>0.5;  Negative(Red):OD600<0.2 Weak(Yellow):0.2≤OD600≤0.5; n = 3 
 
 
Nitrogen Source Assimilation 
 
 The nitrogen assimilation patterns were similar for all species, except C. glabrata and K. ohmeri. 
(Tables 10, 11 and 12). All species were able to utilize ammonium acetate. All but C. glabrata were able 
to assimilate L-valine, L-proline, glycine, L-arginine and urea. Some variability was present for sodium 
nitrate and D-valine, although only weak or negative results were obtained. Curiously, C. albicans 
reached the positive threshold, an OD600 of greater than 0.5, when grown with sodium nitrate. K. 
ohmeri also demonstrated an ability to absorb many nitrogen sources the other species could not, 
reaching the positive threshold in all sources except sodium nitrite, sodium nitrate and thiamin. As was 
the case with the carbon source assimilation above, most organisms required at least 48 hours to reach 
the positive threshold for any nitrogen source. The CHS controls remained negative. 
  
Table 10: Nitrogen usage profiles of Candida auris and other related species at 24 hours. 






nitrite L-valine glycine L-proline L-arginine D-valine urea thiamin pyridoxin thymine uracil 
















  0381 0.243 0.050556 0.005333 0.070667 0.059 0.060667 0.489333 0.013444 0.048333 0.020444 0.038667 0.040333 0.022 
  0382 0.130667 -0.01311 0.003111 0.063778 0.156667 0.142111 0.356778 0.024 0.025222 0.041333 0.072 0.048889 0.028778 
  0383 0.083222 0.102667 0.002556 0.022222 0.038333 0.046444 0.064 0.043 0.060333 0.042333 0.050111 0.068444 0.046556 
  0384 0.003667 0.016667 0.001111 0.014556 0.007111 0.008333 0.015556 -0.004 0.012778 0.006333 0.010778 0.013778 0.007778 
  0385 0.002333 0.116889 -0.00011 0.003778 0.001111 0.001667 0.001778 0.002333 0.005222 0.001222 0.003 0.002222 0.001222 
  0386 0.332222 0.015111 0.001889 0.145778 0.175444 0.349333 0.428667 0.083111 0.146444 0.063667 0.077444 0.050333 0.045889 
  0387 0.000778 0.004556 -0.00044 0.015556 0.004444 0.024 -0.00122 0.013889 0.000111 -0.00056 0.005444 0 0.013889 
  0388 0.078111 0.061222 0.000778 0.031889 0.056667 0.067556 0.110333 0.051222 0.063667 0.044889 0.042444 0.054222 0.044222 
  0389 0.021667 0.003889 0.000333 0.007333 0.039667 0.013 0.027444 0.012778 0.010222 0.006444 0.009333 0.012556 0.011667 














  0391 0.055889 0.017889 0.002556 0.017 0.021556 0.014222 0.213 0.023111 0.025111 0.007333 0.010333 0.011444 0.002 
  0392 0.156 0.056333 0.001556 0.079111 0.105222 0.098222 0.166556 0.051222 0.139444 0.057111 0.039889 0.041 0.036333 
















  0393 0.036333 0.018778 0.001444 0.044333 0.027667 0.041667 0.037889 0.012778 0.037667 0.008222 0.008889 0.017111 0.022333 






























































0399 0.562 0.091 0.013111 0.138556 0.030333 0.156778 0.517 0.080556 0.402444 0.055667 0.073333 0.075667 0.093556 
















0325 1.273111 -0.07522 -0.09578 -0.08044 -0.08967 -0.09622 -0.02911 -0.09678 -0.07444 -0.095 0.019333 -0.08278 -0.09056 













  0344 0.472333 0.039889 0.001444 0.033111 0.045889 0.020444 0.600444 0.017444 0.014667 0.009111 0.011556 0.008889 0.014111 




























    0.782111 0.039222 0.002333 0.239111 0.258444 0.364556 0.921111 0.079 0.818889 0.071 0.060889 0.078444 0.068444 




Table 11: Nitrogen usage profiles of Candida auris and other related species at 48 hours. 
    ammonium sulfate sodium nitrate sodium nitrite L-valine glycine L-proline L-arginine D-valine urea thiamin pyridoxin thymine uracil 
Species Isolate                           
Candida auris 
  0381 0.864 0.101556 0.024889 0.497556 0.666667 0.637 1.174444 0.075444 0.537778 0.063111 0.092556 0.083556 0.077 
  0382 0.660444 0.063889 0.003667 0.499778 0.806333 0.963222 0.864111 0.099778 0.641111 0.074889 0.110889 0.254667 0.078556 
  0383 0.768303 0.11652 0.004766 0.57273 0.728752 0.762413 0.966386 0.13169 0.811813 0.105412 0.104252 0.131138 0.133612 
  0384 0.726831 0.120523 0.004939 0.529038 0.704007 0.705568 0.92024 0.129708 0.763517 0.10193 0.103401 0.128388 0.125486 
  0385 0.371556 0.18333 -0.00022 0.047556 0.072222 0.113333 0.376333 0.054778 0.669 0.033444 0.031222 0.079222 0.160222 
  0386 1.131222 0.043778 0.001111 0.937667 1.013222 0.960111 1.189333 0.185667 0.989889 0.162222 0.152222 0.149 0.144778 
  0387 0.747867 0.114344 0.004389 0.504378 0.646844 0.649789 0.918844 0.1283 0.714389 0.104633 0.099122 0.1221 0.1203 
  0388 1.037 0.131 0.006222 0.735556 1.028222 0.922333 1.240778 0.186222 1.062111 0.192778 0.188222 0.202444 0.170889 
  0389 0.812333 0.122667 0.000333 0.748556 0.894667 0.925556 1.161667 0.255111 0.791222 0.102111 0.083667 0.101333 0.099111 
  0390 0.735333 0.112 0.002667 0.775111 0.951889 0.914 1.088 0.031333 1.128667 0.112 0.067778 0.074778 0.179889 
Candida. duobushaemulonii 
  0391 0.865222 0.109556 0.005333 0.617333 0.876889 0.627111 1.056444 0.333667 0.986111 0.055667 0.042222 0.069111 0.293 
  0392 1.013444 0.202778 0.002333 0.686222 0.939667 0.766222 1.153222 0.138556 1.089 0.162333 0.090333 0.200444 0.099333 
  0394 1.010148 0.169408 0.015556 0.685333 1.006815 0.533778 1.230259 0.201333 1.081222 0.122185 0.06963 0.132555 0.186481 
Candida haemulonii 
  0393 0.797444 0.111889 0.031444 0.370889 0.699111 0.778222 1.143222 0.055778 0.994778 0.056889 0.052667 0.083 0.167778 
  0395 0.735778 0.124778 0.001 0.407556 1.032556 0.504889 0.850111 0.129556 0.791333 0.073 0.044222 0.086778 0.074556 
Kodameaea ohmeri 
  0396 1.039667 0.224667 0.09 1.041667 1.163333 1.112 1.186667 0.369 1.169667 0.382 0.593 0.827333 0.791333 
Candida krusei 
  0397 0.183222 0.260333 -0.00567 0.175 0.194889 -0.00367 0.152556 0.143778 0.095111 0.017778 0.014111 0.003778 0.020778 
Candida Lusitaniae 
  0398 0.907778 0.128 0.047667 0.998444 1.147111 1.337222 1.276111 0.071444 1.141444 0.197 0.182889 0.066667 0.028889 
Saccharomyces cerevisiae 
  0399 0.924889 0.074 0.026667 0.841 0.076444 0.877556 1.056111 0.056556 1.060111 0.059778 0.056444 0.067222 0.056556 
  0400 0.719444 0.060556 0.059111 0.629556 0.108444 0.572 0.795222 0.052 0.842556 0.055556 0.050222 0.052667 0.032333 
Candida glabrata 
  0325 1.251 -0.09111 -0.10867 -0.08967 -0.07678 -0.10767 -0.01344 -0.10889 -0.08589 -0.10756 -0.00133 -0.09567 -0.10244 
  0333 0.827667 -0.22244 -0.23144 -0.14025 -0.1285 -0.15159 -0.0147 -0.21567 -0.16772 -0.21756 -0.22444 -0.22156 -0.21167 
Candida parapsilosis 
  0344 0.961 0.089333 0.013444 0.284333 0.174444 0.242444 1.080444 0.044667 0.086444 0.024222 0.041111 0.026667 0.042444 
  0340 1.040784 0.148874 0.015598 0.429674 0.10467 0.394333 1.889417 0.05479 0.106566 0.033038 0.072562 0.046999 0.065554 
Candida tropicalis 
  0345 0.875222 0.204667 0.016222 0.766111 0.913556 0.776667 0.892222 0.079667 0.942889 0.100222 0.104 0.133111 0.112111 
Candida albicans 
  Y-12983 0.853111 0.382889 0.003667 0.918778 0.983667 1.001778 0.986111 0.174889 1.041333 0.121667 0.113778 0.118222 0.112889 





Table 12: Nitrogen usage profiles of Candida auris and other related species at 72 hours. 
    ammonium sulfate sodium nitrate sodium nitrite L-valine glycine L-proline L-arginine D-valine urea thiamin pyridoxin thymine uracil 
Species Isolate                           
Candida auris 
  0381 1.297667 0.118 -0.023 1.072556 1.233889 1.260778 1.420778 0.093 1.134889 0.066111 0.107778 0.082778 0.088889 
  0382 0.594333 0.150444 0.003444 0.895111 1.156889 1.233778 1.029556 0.288667 0.909667 0.167 0.299556 0.420222 0.130222 
  0383 0.774222 0.161444 0.007667 0.847333 1.003 1.142333 1.158889 0.272 1.330444 0.158667 0.166111 0.126889 0.278333 
  0384 0.831 0.295889 0.003778 0.622778 1.356444 0.856667 1.276778 0.178778 1.103222 0.113333 0.150333 0.175667 0.194333 
  0385 0.738333 0.390222 -0.001 0.929333 1.264778 0.920778 0.917778 0.150667 1.345 0.143667 0.126778 0.162111 0.361444 
  0386 1.356889 0.068222 0.038556 1.253889 1.330778 1.267222 1.336111 0.227444 1.274333 0.200556 0.196111 0.194556 0.192444 
  0387 0.983422 0.209155 0.0042 1.017 1.217156 1.076722 1.212789 0.212144 1.207189 0.158067 0.159367 0.188222 0.1914 
  0388 1.111111 0.238333 0.004111 1.206 1.269333 1.272556 1.325556 0.246778 1.228333 0.239778 0.241778 0.254556 0.217889 
  0389 1.107667 0.21111 0.006556 1.175556 1.352889 1.339222 1.340667 0.379222 1.168 0.141556 0.110111 0.130444 0.128111 
  0390 0.666333 0.23111 0.003222 0.913667 1.009778 1.017778 0.992889 0.056 1.239556 0.126667 0.078889 0.153889 0.182 
Candida duobushaemulonii 
  0391 1.113111 0.145111 0.026667 1.114444 1.256444 1.105444 1.261556 0.438667 1.255222 0.102778 0.074444 0.106889 0.502 
  0392 1.270556 0.488 0.002111 1.402222 1.527556 1.426222 1.537111 0.285222 1.560889 0.469222 0.117444 0.403111 0.217444 
  0394 1.112259 0.319222 0.022444 1.174741 1.311667 0.955074 1.317185 0.328556 1.319889 0.230778 0.086963 0.245926 0.299 
Candida haemulonii 
  0393 1.074333 0.135556 0.080333 0.845778 1.100556 1.073 1.250111 0.101222 1.271222 0.096222 0.092333 0.112778 0.215222 
  0395 0.786889 0.176222 0.004667 0.851444 1.120889 0.492667 0.879667 0.263444 0.917111 0.099222 0.059333 0.172444 0.113222 
Kodamaea ohmeri 
  0396 1.330889 0.445556 0.287889 1.33 1.571444 1.435778 1.429111 0.532111 1.330444 0.5 0.770778 1.131222 1.034333 
Candida krusei 
  0397 1.062444 0.116889 0.089 0.999444 0.560778 0.979778 1.396 0.333778 1.168444 1.274556 0.172444 0.151222 0.122333 
Candida Lusitaniae 
  0398 1.156889 0.144333 0.069111 1.164778 1.260889 1.399556 1.377778 0.042222 1.229889 0.190222 0.167444 0.054111 0.042556 
Saccharomyces cerevisiae 
  0399 1.001222 0.082556 0.046111 0.92 0.370222 1.004667 1.086778 0.065778 1.041556 0.056556 0.064889 0.061222 0.060444 
  0400 0.858333 0.071 0.111 0.723444 0.514111 0.776444 0.914667 0.055333 0.949111 0.064889 0.058889 0.071556 0.040333 
Candida glabrata 
  0325 1.134667 -0.098 -0.11044 -0.04833 -0.00856 -0.10644 0.031556 -0.12067 -0.09411 -0.11867 0.001333 -0.095 -0.11489 
  0333 1.260416 -0.14862 -0.21 -0.08848 -0.01469 -0.19292 0.060757 -0.13 -0.09523 -0.12747 0.002564 -0.18253 -0.11713 
Candida parapsilosis 
  0344 1.084667 0.125889 0.062556 1.102778 0.499778 1.075 1.262778 0.122 0.880222 0.06 0.536 0.259111 0.225778 
  0340 1.259833 0.132271 0.095859 1.521669 0.822361 0.609889 2.059369 0.213444 0.885558 0.076875 0.682587 0.489966 0.338873 
Candida tropicalis 
  0345 1.005889 0.255444 0.031 0.902556 1.020667 0.925889 0.946111 0.075111 0.940889 0.125556 0.112333 0.168556 0.203 
Candida albicans 
  Y-12983 0.914889 0.684889 0.003 0.930556 0.996333 1.084222 1.029111 0.214222 1.039222 0.128556 0.129778 0.130889 0.109889 







 The different isolates displayed a similar pattern of fermentation and assimilation (Tables 13 and 
14). The Microlog system classifies results as positive, partial, or negative. These are colorized as green, 
yellow and red, respectively. In the case of isolates 0385, 0398 and 0399, which were tested in triplicate, 
three results may be listed. This is only the case when one of the replicates disagreed with the others. If 
only one result is presented, all three replicates were in accord. There are, however, several differences 
between isolates. The type strain, isolate number 0381, displays some interesting discrepancies with the 
other isolates. It is the only isolate that did ferment or assimilate n-acetyl-D-glucosamine. It was also the 
only isolate of C. auris that presented a negative result for assimilation of 2-keto gluconic acid. The other 
isolates presented at least partial growth here. Isolate 0381 also displayed more positive results in the 
assimilation of the combinations of D-xylose and another carbon source. Isolates 0384, 0385, and 0386 
also assimilated most of these. With one exception, however, all of these instances of growth were only 
in the partial range. Without the C. auris in the database, it was misidentified in every case (Table 15). In 
fact, the only species the system correctly identified was C. haemulonii (AR0393), even though C. 
lusitaniae (AR0398) and S. cerevisiae (AR0399) were tested and both species are listed in the database. 
In all cases, the most likely identity given by the software for C. auris was either C. haemulonii or 
Rhodotorula acheniorum. These identifications did appear to be aligned with the clades, although the 
probability values of correct identification were far lower for some than others (Table 15).  
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Table 15: Microlog Identification of Panel Isolates, colorized by clade. 
Isolate Species Identification Probability 
0381 Candida auris Rhodotorula acheniorum 0.99 
0382 Candida auris Candida haemulonii 0.844 
0383 Candida auris Rhodotorula acheniorum 0.916 
0384 Candida auris Rhodotorula acheniorum 0.994 
0385 Candida auris Candida haemulonii 0.988 
0386 Candida auris Candida haemulonii 0.959 
0387 Candida auris Candida haemulonii 0.964 
0388 Candida auris Candida haemulonii 0.913 
0389 Candida auris Candida haemulonii 0.714 
0390 Candida auris Candida haemulonii 0.896 
0391 Candida duobushaemulonii Candida haemulonii 0.997 
0393 Candida haemulonii Candida haemulonii 0.993 
0398 Candida lusitaniae Candida haemulonii 0.93 
0399 Saccharomyces cerevisiae Zygosaccharomyces fermentati 0.804 
 




 Higher concentrations of many essential oils negatively impacted the growth of all species. All 
essential oils except eucalyptus, lemon, grapefruit and bitter orange displayed inhibitory activity at the 
concentrations tested (Tables 16 and 17).  Bergamot, cinnamon bark, cinnamon leaf, clove bud, 
geranium, lemongrass, lime peel, peppermint, spearmint, and tea tree oils all showed inhibitory activity 
at concentrations considered safe for dermal use (Appendix II). Basil and lavender oils had MIC values 
above the recommended safe concentrations and the remainder had no maximum concentration listed 
(Appendix II). Of the essential oils that displayed lethal activity against C. auris, only bergamot, lavender 
and basil oils were above the safe concentrations.  Interestingly, C. auris (AR0391 and AR0395) displayed 
mostly lower MIC and MFC values than either C. lusitaniae (AR0398) or S. cerevisiae (AR0399). Both 
strains of C. auris also displayed MIC and MFC values within one microdilution of each other, except for 
in the case of the manuka and basil oil MIC values. Cinnamon leaf, cinnamon bark, clove bud and 
lemongrass oils displayed the most potent antifungal activity, with cinnamon bark displaying the lowest 
MIC and MFC values against all organisms. In some cases, the MIC was below the tested concentrations 
and required further dilution during the checkerboard assays. 
Table 16: MIC by percentage (v/v) of select essential oils against C. auris (0381, 385), Candida lusitaniae 
(0398) and Saccharomyces cerevisiae (0399). Tests were run in triplicate.  
Essential Oil 0381 0385 0398 0399 
Tea Tree 0.25% 0.13% 0.50% 0.50% 
Geranium 0.13% 0.06% 0.50% 0.25% 
Lime Peel 0.25% 0.13% 1.0% >1.0% 
Eucalyptus >1.0% >1.0% >1.0% >1.0% 
Peppermint 0.25% 0.25% 1.0% 1.0% 
Manuka 0.25% 1% >1.0% 1.0% 
Clove Bud 0.01% 0.02% 0.06% 0.25% 
Myrrh 0.13% 0.13% 1.0% 1.0% 
Spearmint 0.13% 0.06% 0.50% >1.0% 
Cinnamon Leaf <0.01% <0.01% 0.13% 0.25% 
Cinnamon Bark <0.01% <0.01% <0.01% <0.01% 
Bergamot 0.25% 0.13% >1.0% >1.0% 
Lemon >1.0% >1.0% >1.0% >1.0% 
Frankincense 1.0% 1.0% >1.0% >1.0% 
Coriander 0.50% 0.50% 1.0% 1.0% 
Bitter Orange >1.0% >1.0% >1.0% >1.0% 
Grapefruit >1.0% >1.0% >1.0% >1.0% 
Lavender 1.0% 1.0% 1.0% >1.0% 
Ginger 1.0% >1.0% >1.0% >1.0% 
Basil 0.13% 0.50% >1.0% >1.0% 
Lemongrass 0.02% 0.03% 0.13% 0.25% 
 
Table 17: MFC of select essential oils against C. auris (0381, 385), Candida lusitaniae (0398) and 
Saccharomyces cerevisiae (0399).  
Essential Oil 0381 0385 0398 0399 
Tea Tree 0.50% 1.0% ND 1.0% 
Geranium 0.50% 0.25% 1.0% 0.50% 
Peppermint 1.0% 1.0% ND ND 
Clove Bud 0.06% 0.13% ND ND 
Cinnamon Leaf 0.50% 0.25% 0.50% 0.50% 
Cinnamon Bark 0.02% 0.02% 0.01% 0.02% 
Bergamot 0.50% 0.25% ND ND 
Coriander 1.0% 1.0% 1.0% ND 
Lavender 1.0% ND 1.0% ND 
Basil 1.0% 1.0% ND ND 





 Only lemongrass, clove bud and cinnamon bark oils displayed any inhibition in vapor phase 
(Table 18). These oils were also the most effective in direct contact. All three oils were lethal at 100 μL. 
At 10 μL, cinnamon bark again displayed lethality, clove bud oil showed complete inhibition, and 
lemongrass oil elicited no effect. 
Table 18: Antifungal activity of essential oils in vapor-phase on C. auris (0385). 
Essential Oil Result Essential Oil Result 
Tea Tree No inhibition Cinnamon Bark (1.0μL) No inhibition 
Geranium No inhibition Bergamot No inhibition 
Lime Peel No inhibition Lemon No inhibition 
Eucalyptus No inhibition Frankinsence No inhibition 
Peppermint No inhibition Coriander No inhibition 
Manuka No inhibition Bitter Orange No inhibition 
Clove Bud (100 μL) Lethal Grapefruit No inhibition 
Clove Bud (10 μL) Inhibition Lavender No inhibition 
Myrrh No inhibition Ginger No inhibition 
Spearmint No inhibition Basil No inhibition 
Cinnamon Leaf No inhibition Lemongrass (100 μL) Lethal 
Cinnamon Bark (100 μL) Lethal Lemongrass (10 μL) No inhibition 
Cinnamon Bark (10 μL) Lethal     




 A range of interactions were observed between the essential oils and the various antifungal 
drugs (Tables 19, 20, 21 and 22). FICI values ranged from 0.0625 to 5.0. This range includes at least one 
instance of each interaction. Antagonism was only present with the combination amphotericin B and 
clove bud oil. However, clove bud oil also displayed synergistic activity with fluconazole for all three 
organisms and an additive to synergistic association with flucytosine. Lemongrass oil was generally 
additive with all of the drugs. The only exception was an indifferent association with amphotericin B 
when used on C. lusitaniae and a synergistic one when used with micafungin on S. cerevisiae. Cinnamon 
oil was generally indifferent in most cases. When looked at from the perspective of the drugs, the 
results were more varied. All drugs except amphotericin B had instances of synergism, while 
amphotericin B had the only instances of antagonism. All four drugs displayed instances of indifference 
and additivity.  
Table 19: Interactions between select antifungal drugs and essential oils on C. auris. 
Antifungal Essential Oil FIC(AF) FIC(EO) FICI Interpretation 
Micafungin Cinnamon Bark 1 1 2 Indifferent 
Micafungin Clove Bud 1 1 2 Indifferent 
Micafungin Lemongrass 0.5 0.125 0.625 Additive 
Flucytosine  Cinnamon Bark 0.5 0.25 0.75 Additive 
Flucytosine  Clove Bud 0.0625 0.125 0.1875 Synergistic 
Flucytosine  Lemongrass 0.125 0.5 0.625 Additive 
Amphotericin B Cinnamon Bark 1 0.5 1.5 Indifferent 
Amphotericin B Clove Bud 4 0.5 4.5 Antagonistic 
Amphotericin B Lemongrass 0.25 0.5 0.75 Additive 
Fluconazole Cinnamon Bark 1 0.5 1.5 Indifferent 
Fluconazole Clove Bud 0.03125 0.25 0.28125 Synergistic 
Fluconazole Lemongrass 0.125 0.5 0.625 Additive 
 
Table 20: Interactions between select antifungal drugs and essential oils on C. lusitaniae. 
Antifungal Essential Oil FIC(AF) FIC(EO) FICI Interpretation 
Micafungin Cinnamon Bark 1 1 2 Indifferent 
Micafungin Clove Bud 0.5 1 1.5 Indifferent 
Micafungin Lemongrass 0.125 0.5 0.625 Additive 
Flucytosine  Cinnamon Bark 1 0.5 1.5 Indifferent 
Flucytosine  Clove Bud 0.25 0.5 0.75 Additive 
Flucytosine  Lemongrass 0.5 0.5 1 Additive 
Amphotericin B Cinnamon Bark 1 0.5 1.5 Indifferent 
Amphotericin B Clove Bud 4 1 5 Antagonistic 
Amphotericin B Lemongrass 1 0.25 1.25 Indifferent 
Fluconazole Cinnamon Bark 2 0.5 2.5 Indifferent 
Fluconazole Clove Bud 0.03125 0.03125 0.0625 Synergistic 











Table 21: Interactions between select antifungal drugs and essential oils on S. cerevisiae. 
Antifungal Essential Oil FIC(AF) FIC(EO) FICI Interpretation 
Micafungin Cinnamon Bark 1 1 2 Indifferent 
Micafungin Clove Bud 0.5 0.5 1 Additive 
Micafungin Lemongrass 0.25 0.125 0.375 Synergistic 
Flucytosine  Cinnamon Bark 1 0.75 1.75 Indifferent 
Flucytosine  Clove Bud 0.25 0.5 0.75 Additive 
Flucytosine  Lemongrass 0.5 0.5 1 Additive 
Amphotericin B Cinnamon Bark 1 0.5 1.5 Indifferent 
Amphotericin B Clove Bud 4 1 5 Antagonistic 
Amphotericin B Lemongrass 0.25 0.5 0.75 Additive 
Fluconazole Cinnamon Bark 1 0.5 1.5 Indifferent 
Fluconazole Clove Bud 0.25 0.25 0.5 Synergistic 
Fluconazole Lemongrass 0.125 0.5 0.625 Additive 
 
Table 22: Summary of Essential Oil-Drug Interactions. 
  Cinnamon Bark Clove Bud Lemongrass 
Micafungin Indifferent Indifferent-Additive Additive-Synergistic 
Flucytosine Indifferent-Additive Additive-Synergistic Additive 
Amphotericin B Indifferent Antagonistic Indifferent-Additive 







 A rapid means to estimate and standardize microbial populations is essential to performing high 
throughput methods, such as microbial identification and antimicrobial testing. While the use of OD600 
as a means to estimate population is not a new concept, it was used here on several novel organisms, 
namely Candida auris. At any point when approximating cell density is required, reading the absorbance 
of a sample is much faster than counting using a hemocytometer or traditional plates. The purpose here 
was to increase the speed of preparation and precision of starting populations. Because absorbance is a 
linear function of cell density, with single and uniform celled organisms, a small but representative range 
of population densities and their respective absorbance values allow the creation of a standard curve 
that can extrapolate population values outside the range initially used to construct the curve. This 
relation will be slightly different for different species due to a variety of factors. The factor with the 
greatest impact is likely the cell size. Larger cells absorb more light because there is simply more 
biomass.  It was observed that S. cerevisiae is qualitatively much larger than C. auris (Figure 17). This 
contributes to the reason why the slope of the S. cerevisiae curve was about a quarter of the slope of 
the C. auris curve. It was also noticed that some of the curves fluctuated more than others. The most 
pronounced of these were the curves drafted for C. glabrata, C. parapsilosis and C. tropicalis. In each of 
these instances, the organisms were noticed to aggregate more heavily than the other species. This 
aggregation of cells would cause more variability in the curve. CHS contains a small amount of Tween 80 
to act as a detergent and prevent this. These three organisms still maintained some aggregation despite 
this. Standard curves such as these could also be used as a replacement for other standards that 
estimate population based on turbidity, such as MacFarland standards. To replace the turbidity 
standards, however, either the starting population predicted by the turbidity standard or its absorbance 
value need to be known. Standard curves are more precise than visually comparing culture to the 
turbidity standards because the sensor of a spectrophotometer is more sensitive than the human eye.  
Methylene-Blue Staining 
 
Methylene blue was successful in differentially staining C. auris to determine viability. Staining is 
simple, inexpensive, and time-efficient when compared to traditional plate counts and could easily be 
applied to many antimicrobial testing methods where assessing viability is desired. Plate counts are 
currently used for this assessment and require two to three days of incubation to obtain results. Using 
methylene blue and a hemocytometer, equivalent results were obtained in less than an hour. Because 
this stain has worked on two different yeast species, it is also reasonable to believe that this method 
could be extended to other Candida species and possibly even other pathogenic yeasts. One limitation 
of this method is that hemocytometers have a lower limit of detection of 104 cells per mL. For testing 
requiring a starting inoculum lower than this, the method could still be used, but an extra dilution step 
would be required and could be a source of error. 
New multi-drug-resistant C. auris isolates continue to be identified. Coupled with the fact that 
many other fungal species are developing resistance to a variety of drugs, this underscores the need for 
production of novel antifungal drugs and higher throughput testing methods. With drug development 
being undermined by misdiagnosis and a lack of funding, cheap and time-saving tools are invaluable for 
combatting this emerging pathogen. Using methylene blue, a low-cost viability estimate can be obtained 
in less than an hour. These qualities can enhance the rapid production of antimicrobials to prevent and 
treat infection by C. auris and thus save lives.  
Carbon and Nitrogen Sources Assimilation Patterns 
 
 The presence of distinctive patterns of carbon and nitrogen source assimilation for Candida 
auris could provide a step towards developing a cheap and effective diagnostic test or enrichment 
medium. Because all species tested utilize galactose except C. auris and C. glabrata, this could provide a 
major differentiating component of diagnostic tests. Tests requiring a negative result would be not ideal, 
and it would thus be wise to include other tests for verification. Using a quad plate, a simple test media 
containing quadrants with either D-galactose, D-xylose, D-raffinose and dodecane as a sole carbon 
source would be worth examining. C. auris is unable to assimilate either D-galactose or D-xylose, so the 
two substrates could be used to rule out C. auris when examining a suspected isolate.  C. auris will 
assimilate D-raffinose and dodecane, so these carbon sources could help differentiate C. auris from the 
related species that cannot utilize them.  
Lactose, L-arabinose and dulcitol presented variable results for the different isolates of C. auris. 
These discrepancies were not aligned with clade. These were each retested repeatedly, and the results 
were consistent. In addition, the standard error of the mean calculated from each triplicate could not 
account for the variation between isolates (Table 23). It is, however, quite common for this type of 
variability to appear between isolates of the same yeast, especially when they are geographically 
separated [68, 69]. According to one study, the metabolic capabilities of several isolates of 
Saccharomyces paradoxus from a geographic region the size of a state were examined. The results show 
that the ability to utilize various substrates of a core group of carbon sources, such as glucose and 
sucrose, that are more common and nutritive is conserved among isolates. The remainder, which the 
study dubs the auxiliary group, includes less common and nutritive substrates like lactose and L-
arabinose. The capability to utilize these is more variable and depends on the organism’s environmental 
history [69]. This makes sense, as it is inefficient to maintain genes and enzymes to process less nutritive 
or absent substrates when more valuable ones are readily available. This type of variability can also pose 
a problem for utilization-based diagnostic test. Substrates from the core group are not appropriate 
because the ability to utilize them will likely be conserved between related species. On the other hand, 
many of the auxiliary sources are not good choices because they are not conserved between isolates of 
the same species. The former case could yield false positive identification, while the latter could yield 
false negative results. Either type of misidentification would lead to mistreatment, thus complicating the 
clinical outcome. 
The nitrogen sources yielded little in differential potential. All isolates tested showed very 
similar patterns of assimilation. The differences were primarily in the OD600 range that was classified as 
weak growth and the variability was not isolated to any one species. “Weak” growth could be the result 
of carryover of media or nutrients within the cell. This would allow the cells to continue to grow and 
reach a low density before running out of nutrients. In total, more studies are needed to generate a 
diagnostic media. More carbon and nitrogen sources can be tested to find additional combinations that 
can differentiate between C. auris and related species. Similarly, additional isolates of the species 
besides C. auris should be included.  Many species had only one isolate tested, and several species that 
turn up as misidentifications were not tested at all (Table 1). Many species had only one isolate tested, 
and this would help to validate the results for species examined here. By examining additional species 
that were not tested here, it would help to ensure that the assimilation patterns of C. auris are not 
shared by these other species and to avoid future misidentification. Further studies could also explore 
the situations where organisms could not assimilate some sources. Sodium nitrite is a well-known food 
preservative. Not only were nearly all isolates unable to assimilate it, it is possible that they were 
inhibited by it as well. This could be true of the other negative results as well. In any case, the metabolic 
capabilities are a necessary component to understanding any organism. These fundamental properties 
often contribute to the pathogenic potential and the vulnerabilities in the organism’s defense and 
warrant exhaustive exploration. 
Table 23: Selected standard error of the mean for  
carbon source utilization testing. 
Strain Lactose Arabinose Dulcitol
0381 0.0050 0.0721 0.0543
0382 0.0729 0.0257 0.0298
0383 0.0348 0.0497 0.2013
0384 0.0900 0.0217 0.0162
0385 0.0443 0.0135 0.0329
0386 0.1570 0.1185 0.0300
0387 0.0194 0.1057 0.0984
0388 0.0401 0.0561 0.0032
0389 0.0511 0.0878 0.0314
0390 0.0308 0.0426 0.0053  
Identification and Substrate Utilization using the Biolog YT Plate 
 
 The utilization data gathered using the Biolog YT plate adds significantly to the data produced in 
the carbon source testing described above. Despite the fact that the Biolog system did not accurately 
identify the Candida lusitaniae or Saccharomyces cerevisiae isolates used in this study, the information 
provided by the system is valuable. The Biolog YT plate contains 35 carbon source fermentation assay, 
48 sole carbon source assimilation assays and 11 assimilation assays for paired carbon sources. Some of 
the carbon sources were the same as those previously tested. These were D-galactose, D-glucose, 
maltose, sucrose, D-raffinose, D-mannitol, L-arabinose, glycerol and D-xylose. The results for all 
overlapping sources aside from L-arabinose, glycerol and D-xylose agree with the previous results for C. 
auris. However, each of these sources resulted in partial growth on the Biolog plate. For L-arabinose and 
glycerol, this doesn’t align with the 72-hour results. However, the Biolog plates were only incubated for 
48-hours. When looking at the 48-hour utilization results, L-arabinose and glycerol show only weak 
growth. They do not reach the positive threshold until 72 hours, thus aligning with the Biolog results. 
Isolate 0381 shows partial growth in the D-xylose well of the Biolog plate. It also utilized several of the 
D-xylose combinations. Since this isolate was not tested in triplicate, it becomes difficult to rule out 
common sources of error such as contamination or nutrient transfer. This could be the cause of the 
differences between this isolate and the others. However, discussion with a colleague (Dr. Joe Sexton, 
mycotic diseases branch, CDC) working with this panel have reported similar metabolic oddities in this 
strain. More replication will be needed to confirm these anomalies.  
Other prevalent issues with comparing these results come from the proprietary nature of the 
Biolog system and thus many specific parameters are not released to the end-user. The wavelength used 
by the turbidimeter and thus the starting population are not known, although the starting populations 
for the Biolog plates were visibly more turbid. The concentrations of the carbon sources are also not 
known in the YT plates. This is relevant because the chemicals may be nutritive at some levels, but toxic 
at higher concentrations, either directly or by affecting properties like pH or osmotic pressure of the 
cells [70]. Finally, the thresholds for the partial and positive results on the Biolog plates are unknown. 
This could obviously complicate the comparison if the thresholds for one are significantly different from 
the other. The preparation is also different between the two methods. The Biolog preparation had 
cultures suspended in water, while the other method used CHS. The CHS serves to separate the yeast 
cell aggregates and ensure a more homogenous solution. Thus, the Biolog starting inoculums would 
likely be more variable if the organism tended to aggregate. Even though the comparison must be taken 
with some skepticism, the differences are still worth examining. It is very interesting that, despite the 
variance, the species C. auris was identified as was consisted within each clade. Obviously, more testing 
is needed to validate the trends identified here. Preferably, the methods should be developed by the 
researcher so all parameters are known, and testing conditions can be replicated with the use of the 
Biolog YT plate. 
Antifungal Activity of Essential Oils 
 
 The antifungal activity elicited by the tested essential oils at levels considered safe for dermal 
use further strengthens their potential application in microbial control, and the applications of the 
findings are numerous. First, the antifungal activity is present against multiple species. Essential oils 
have been tested on a range of yeasts and molds [58], and this activity may be expanded to many more. 
The essential oils might be effective in disinfecting formulations for surfaces [71]. Because this activity 
occurred at concentrations considered safe for dermal use, it is reasonable to predict that the essential 
oils could be used in topical remedies for fungal infections. Future work could also examine if this 
antifungal activity is maintained against bloodstream infections. Another line of inquiry that could be 
pursued is to continue this testing with an expanded pool of essential oils. Since only a small number of 
essential oils were tested here, there could be many more with undiscovered potency already widely 
available. As a foil to the broad-spectrum testing, the most effective oils could be analyzed in depth. 
Gas-Chromatography and Mass-Spectrophotometry could be used to identify the most prevalent 
compounds in these essential oils. These prevalent components could then be subjected to the same 
testing as the essential oils themselves. If activity is retained, the components themselves could be used 
in formulations for disinfection or for the treatment of infection. This may be beneficial because 
individual chemicals are much easier to standardize than the essential oils themselves. 
Vapor-Phase Activity of Essential Oils 
 
 Cinnamon Bark, lemongrass and clove bud essential oils all retained their antimicrobial activity 
in vapor-phase. Despite these being the only three that elicited inhibition of growth, the other oils may 
exhibit the same inhibitory activity at higher doses, especially considering that they required greater 
doses in direct contact. In suboptimal conditions outside of growth media, such as on a healthcare 
surface where the organism does not have access to a nutrient-dense substrate, these effects may 
become relevant. The easily diffused vapor-phase oils could have applications in the home or expansive 
areas where surface disinfection is needed. More testing is needed under more controlled conditions to 
ensure the gaseous concentration, even dispersal and contact time of the gaseous oils to truly elucidate 
the vapor-phase activity of the oils, but these results are promising. In addition, much of the additional 
testing mentioned for direct contact above is applicable in vapor phase as well. Additional essential oils 
or the major constituents of the essential oils could be test as they may also display vapor-phase 
antimicrobial activity [60]. The essential oils could also be tested against a widened range of organisms.   
Interaction of Essential Oils and Antifungal Drugs 
 
 Several additive or synergistic combinations of essential oils and antifungal drugs where 
discovered. While additive combinations indicate that the two components are substitutable and thus 
the overall effective dose is not reduced, two points make these valuable discoveries, nonetheless. First, 
even though the overall effective dose is the same as each component alone, the component doses of 
the essential oil and antifungal are reduced and likely the side effects of each [61]. Second, synergism 
may actually be present, despite the checkerboard method indicating otherwise. While the 
checkerboard assay is one of the better options for large scale screening of combinations, other 
methods exist that are more sensitive [61]. Even as the best option for large-scale screening of 
combinations, checkerboard assays are roughly ten to twenty times more labor-intensive than 
traditional microdilution MIC testing when considering the quantity of wells needed to test one 
combination. This has led to less attention and standardization of the method [66]. Because the method 
is still not fully standardized, several things must be considered when evaluating the results. First, 
because microdilutions are utilized, a fairly large range of concentrations is represented over a small 
number of wells, and thus a lower sensitivity. A difference of one microdilution can have significant 
impact on the FICI. To validate the results produced by the checkerboard assay, smaller dilutions can be 
performed. Second, the methods of analysis for this type of synergism assay are still not well defined 
[50]. FICI cutoffs for different interaction categories are different for different publications, and some 
even combine multiple categories [66]. The selection of the well that determines the MIC values in 
combination can significantly impact the results. Thus, a more standardized method of analysis and 
better-defined categories of interaction is needed for the practice of combination therapy to prosper.  
 The results here show a range of interactions. Cinnamon bark oil appears to be the most 
neutral, displaying mostly indifferent interactions with all antifungals tested. Current thought is that the 
essential oil acts by disrupting membrane integrity [72]. The lack of synergism is unexpected in this case, 
as increased membrane permeability should give other drugs greater access to drug targets, as is seen 
with amphotericin b in combination. Further examination could explore the molecular basis for 
cinnamon oil’s mode of action. This may elucidate why there is an apparent lack of interaction with the 
antifungal drugs. 
 Clove bud oil displayed a range of interactions. In all cases but amphotericin b, these 
interactions were generally positive. The primary component of clove oil, eugenol is thought to impact 
yeast cell wall and membrane integrity [73]. In the case of clove oil, the essential oil likely allows 
enhanced access of flucytosine, fluconazole and micafungin to their respective drug targets as with 
combinations of amphotericin B and other antifungals [61]; however, antagonism was observed 
between clove oil and amphotericin. This is worth examining with future work because the conditions 
causing this antagonism could be mimicked by other chemicals in vivo and complicate treatment with 
amphotericin B. Because both appear to act on the cellular envelope, there may be interference 
between the two chemicals. Eugenol has been demonstrated to bind to steroid receptors [74, 75]. 
Sterols and steroids have been demonstrated to inhibit the activity of amphotericin B [76, 77]. It is 
possible that the eugenol behaves similarly to a sterol or steroid and thus impedes the function of 
amphotericin B. It is also possible that clove bud oil and amphotericin B chemically interact and interfere 
with each other’s access to targets. 
 Lemongrass oil displayed positive interactions with all of the tested drugs. While there have 
been attempts to elucidate the mode of action of lemongrass oil, the mechanisms appear to be various 
and dose dependent [78]. In the cited study, cytoplasmic leakage appeared to be low, and the majority 
of the effects of lemongrass oil seem to be targeted on intercellular components. One thought was that 
the lemongrass oil causes the cell to swell [78]. The increased surface area could lead to an increase in 
permeability. However, the primary components of lemongrass oil are citral isomers (terpenoids) [79]. 
Citral has been demonstrated to decrease membrane fluidity [80].  Decreased membrane fluidity has 
been linked to increased susceptibility of drug-resistant bacteria and Candida [81, 82].  
 In total, several potentially therapeutic combinations of essential oils and antifungal drugs were 
uncovered. More data is needed to validate the results in vivo and examine if toxicity towards human 
cells is also increased, but the results thus far are promising. Many other future lines of inquiry are 
possible. First, additional combinations could be screened for synergism. Since synergism screening is 
labor-intensive, these results could be used to carefully select new combinations for screening by 
considering essential oils similar to those tested here and testing them in appropriately matched pairs. 
The major chemicals components of the oils could also be examined in place of the oils. The pool of 
isolates and species of organisms could also be expanded, to see if the interactions extend beyond the 
small group of organisms tested here. Other, more sensitive methods of synergism screening could be 
pursued with the additive combinations to detect any borderline synergism. Finally, the molecular 
modes of actions of the various combinations could be examined. Understanding these could help 
researchers replicate the effects in future drug development.  
Integrative Nature of the Work 
 
 While much of this work was built on classical microbiology, the integrative nature is in the 
application and ramifications of the findings. The work has generated data and techniques that can be 
applied to a wealth of situations. Disease is an interdisciplinary issue and future study would require 
techniques beyond microbiology to answer those questions. To expand the vapor-phase testing to 
better controlled settings and eventually healthcare facilities would require the use of physics to 
determine the variables that yield a treatment appropriate to the setting. Variables such as humidity, air 
current and temperature all impact the dispersal of a vaporous substance, including essential oils. 
Chemistry techniques are required to elucidate the chemical constituents of the essential oils and, 
coupled with molecular biology, to understand why they function alone or in combination the way that 
they do. Genetics is broadly applicable as well. Traits such as resistance to antifungal drugs and essential 
oils are coded into the genetic material of the organisms. The same can be said of the ability of various 
strains to assimilate the different carbon and nitrogen sources and why their capabilities are different 
between strains, clades and species. Looking on the macroscopic scale, ecology will play a fundamental 
role in the application of this work. How do any of the treatments emerging from this data impact the 
microflora of the healthcare environment or people within? Will the use of vaporous essential oils to 
sterilize a hospital room create conditions ideal for hardier and dangerous species? Will the application 
of combination therapy put patients at risk of candidemia or pave the way for other resistant pathogens 
by eliminating the person’s skin and gut flora, much as the overuse of antifungals probably led to the 
rise of Candida auris [26]? Ecological and microbiological techniques will be needed to answer these 
questions. These results could even reach beyond the traditional sciences. Economic analysis is needed 
to assess the cost of any of the treatments arising from this data and their viability as a treatment 
option. Even psychology has its place. For instance, hospitals are a stressful environment for patients. 
One study even shows a higher incidence of depression in those under hospital care than the general 
population [65]. Therefore, some patients are dealing with both medical and psychological disorders. A 
link has also been found between impaired immune function and depression [84]. It has been 
demonstrated that olfactory stimulation can impact mood and that aromatherapy with essential oils 
may help treat depression [85, 86]. It is possible that essential oil aromatherapy could both help control 
the microbial burden of the hospital environment and ease the psychological burden of the patients. It 
would be worth evaluating the psychological changes and clinical outcomes of patients in rooms treated 
with traditional cleaners, such as bleach, as compared to those using natural and pleasant-smelling 
essential oils. 
General Discussion of Research Outcomes 
 
  Despite the need for further study in many areas to fully realize the potential applicability of 
these results, this research has added to the groundwork for future work. The absorbance-population 
curves allow for a quick population estimates of 12 different species using a spectrophotometer, while 
the methylene blue staining allows for the estimation of viability in C. auris and possibly other species of 
pathogenic yeasts. The combination of the carbon and nitrogen assimilation assays and the Biolog trials 
provides some idea into the basic metabolic capabilities of several species, including two novel 
organisms, C. duobushaemulonii and C. auris. The latter portion of the work discovered the MIC values 
of 21 essential oils on three different species of yeast, as well as MFC values of several of the essential 
oils. This research also lays the foundation for future research examining the gaseous activity of these 
oils against Candida auris and possibly other species. Finally, additive or synergistic associations 
between three essential oils and three antifungal drugs were discovered. Candida auris is an emerging 
fungal pathogen that is commonly misidentified and nearly always resistant to at least one antifungal 
drug. Here, we added to the basic understanding of the organism needed to better our diagnostic 
procedures and found several potential treatment options to help control it. Drug-resistant pathogens 
are becoming an increasing problem; this research should aid in controlling this emerging global threat. 
 
  
Appendix I: Identity and Minimum Inhibitory Concentrations of Isolates Used 
AR Bank Num Organism Name Amphotericin B Anidulafungin Caspofungin Fluconazole Flucytosine Isavuconazole Itraconazole Micafungin Posaconazole Voriconazole 
0381 Candida auris 0.38 0.25 0.125 4 2 #N/A 0.125 0.125 0.06 0.03 
0382 Candida auris 0.38 0.25 0.5 16 0.125 #N/A 1 0.25 0.5 0.5 
0383 Candida auris 0.38 1 0.25 128 0.5 #N/A 0.5 1 0.5 4 
0384 Candida auris 0.5 2 16 128 0.5 #N/A 1 2 0.5 1 
0385 Candida auris 0.5 1 0.5 >256 0.5 #N/A 1 0.5 1 16 
0386 Candida auris 0.5 1 0.5 >256 0.5 #N/A 0.5 0.25 0.5 16 
0387 Candida auris 0.75 0.5 0.25 8 8 #N/A 0.5 0.5 0.25 0.06 
0388 Candida auris 1.5 0.5 1 >256 0.125 #N/A 0.5 0.125 0.25 2 
0389 Candida auris 4 1 0.5 256 128 #N/A 0.25 0.25 0.125 4 
0390 Candida auris 4 1 0.5 >256 128 #N/A 1 0.25 0.5 8 
0391 Candida duobushaemulonii #N/A 0.06 0.03 8 <0.125 #N/A 0.5 0.125 0.25 0.25 
0392 Candida duobushaemulonii #N/A 0.06 0.03 8 <0.125 #N/A 0.5 0.125 0.25 0.06 
0393 Candida haemulonii #N/A 0.25 0.125 0.5 <0.125 #N/A 0.125 0.25 0.125 0.008 
0394 Candida duobushaemulonii #N/A 0.03 0.008 4 <0.125 #N/A 0.06 0.06 0.016 0.125 
0395 Candida haemulonii #N/A #N/A #N/A #N/A #N/A #N/A #N/A #N/A #N/A #N/A 
0396 Kodamaea ohmeri #N/A 1 0.25 2 0.5 #N/A 0.125 0.5 0.06 0.03 
0397 Candida krusei #N/A 0.03 0.125 64 2 #N/A 1 0.125 1 1 
0398 Candida lusitaniae 0.38 0.125 0.125 1 <0.125 #N/A 0.125 0.125 0.5 0.016 
0399 Saccharomyces cerevisiae #N/A 0.125 0.06 2 <0.125 #N/A 0.06 0.25 0.5 0.03 
0400 Saccharomyces cerevisiae 0.032 0.5 0.5 1 <0.125 #N/A 0.5 0.5 0.5 0.06 
0314* Candida glabrata 0.38 1 0.5 64 <0.12 #N/A >16 1 16 4 
0315* Candida glabrata 0.38 2 16 4 >256 #N/A 1 4 1 0.25 
0316* Candida glabrata 0.05 1 1 4 <0.12 #N/A 0.25 0.25 0.25 0.06 
0317* Candida glabrata 0.19 0.5 1 32 <0.12 #N/A 1 0.25 1 0.5 
0318* Candida glabrata 0.19 4 16 32 <0.12 #N/A 1 4 1 1 
0319* Candida glabrata 0.125 0.5 1 4 <0.12 #N/A 0.5 2 0.25 0.12 
0320* Candida glabrata 0.19 0.5 1 4 <0.12 #N/A 1 0.25 1 0.12 
0321* Candida glabrata 0.09 2 4 64 <0.12 #N/A 1 1 2 2 
0322* Candida glabrata 0.19 2 2 8 <0.12 #N/A 0.5 0.25 0.5 0.12 
0323* Candida glabrata 0.19 4 16 4 <0.12 #N/A 0.25 4 0.25 0.06 
0324* Candida glabrata 0.25 4 16 8 0.12 #N/A 0.5 2 0.5 0.25 
0325 Candida glabrata 0.38 4 >16 128 <0.12 #N/A 16 4 8 16 
0326* Candida glabrata 0.016 0.06 0.06 4 <0.12 #N/A 1 0.015 1 0.125 
0327* Candida glabrata 0.25 0.125 0.125 16 0.25 #N/A 1 0.015 1 0.25 
0328* Candida glabrata 0.25 0.03 0.03 8 <0.12 #N/A 0.5 0.015 0.5 0.25 
0329* Candida glabrata 0.19 0.06 0.06 8 <0.12 #N/A 1 0.03 1 0.25 
0330* Candida glabrata 0.19 0.03 0.06 8 <0.12 #N/A 1 0.015 1 0.25 
0331* Candida glabrata 0.25 0.03 0.06 64 <0.12 #N/A 2 0.015 2 1 
0332* Candida glabrata 0.125 0.06 0.06 128 <0.12 #N/A 4 0.015 2 4 
0333 Candida glabrata 0.125 0.06 0.06 64 <0.12 #N/A 1 0.03 2 1 
0334* Candida glabrata 0.125 0.06 0.06 128 <0.12 #N/A >16 0.03 >16 4 
0335 Candida parapsilosis 0.19 4 0.5 16 0.125 #N/A 0.5 1 0.25 1 
0336* Candida parapsilosis 0.047 1 0.25 32 <0.12 #N/A 0.125 1 0.125 1 
0337* Candida parapsilosis 0.094 1 0.25 64 <0.12 #N/A 0.125 0.5 0.125 1 
0338* Candida parapsilosis 0.125 1 1 16 <0.12 #N/A 0.5 1 0.25 0.25 
0339* Candida parapsilosis 0.047 1 0.25 32 0.25 #N/A 0.25 1 0.25 0.5 
0340* Candida parapsilosis 0.03 2 0.25 0.05 0.125 #N/A 0.125 0.5 0.125 0.015 
0341* Candida parapsilosis 0.023 1 0.5 0.5 0.125 #N/A 0.06 1 0.06 0.015 
0342* Candida parapsilosis 0.023 2 0.5 0.5 0.125 #N/A 0.06 2 0.06 0.015 
0343* Candida parapsilosis 0.06 0.5 0.25 1 0.125 #N/A 0.125 1 0.125 0.06 
0344 Candida parapsilosis 0.06 2 0.25 0.25 <0.12 #N/A 0.03 1 0.06 0.015 
0345 Candida tropicalis 0.38 0.06 0.06 >256 <0.12 #N/A >16 0.06 >16 16 
NRRL-Y12983 Candida albicans #N/A #N/A #N/A #N/A #N/A #N/A #N/A #N/A #N/A #N/A 
Isolate #0381-0400 from Candida auris panel, Isolate # 0323-0345 from Drug Resistant Candida Species panel, adapted from [28] 
*Not used in data presented, but included for completeness 
 
Appendix II: Layout of the Biolog YT Plate 




























D-psicose L-sorbose salicin D-mannitol D-sorbitol D-arabitol xylitol glycerol tween 80 
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maltitol D-mannitol D-sorbitol adonitol D-arabitol xylitol I-erythritol glycerol tween 80 L-
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Appendix III: Essential Oils Examined 
Essential Oil Species MSDC(%)* 
Basil Osimum basilicum 0.10 
Bergamot Citrus bergamium 0.40 
Bitter Orange Citrus aurantium 1.25 
Cinnamon 
Bark 
Cinnamomum zeylancium 0.07 
Cinnamon 
Leaf 
Cinnamomum zeylancium 0.60 
Clove Bud Syzygium aromaticum 0.50 
Coriander Coriandrum sativum NA 
Eucalyptus Eucalyptus globulus 20.00 
Frankincense Boswellia carteri NA 
Geranium Pelargonium graveolens 17.50 
Ginger Zingiber officinale NA 
Grapefruit Citrus paradisi 4.00 
Lavender Lavandula angustifolia 0.10 
Lemon Citrus limon 2.00 
Lemongrass Cymbopogon flexuosus 0.70 
Lime Peel Citrus aurantifolia 0.70 
Manuka Leptospermum scoparium NA 
Myrrh Commiphora myrrha NA 
Peppermint Mentha piperita 5.40 
Spearmint Mentha spicata 1.70 
Tea Tree Melaleuca alterenifolia 15.00 




Appendix IV: Supply and Equipment List 
Item Name Manufacturer Item Number 
Glycerol Sigma Aldrich G5516 
Yeast Nitrogen Base w/o Amino Acids Sigma Aldrich Y0626 
D-glucose Sigma Aldrich G8270 
D-galactose Sigma Aldrich G0750 
L-arabinose Sigma Aldrich A3256 
D-xylose Sigma Aldrich X1500 
Maltose Sigma Aldrich M5885 
Lactose Sigma Aldrich L254 
Sucrose Sigma Aldrich S0389 
D-raffinose Sigma Aldrich 83400 
Maltodextrin Sigma Aldrich 419680 
Dulcitol Sigma Aldrich D0256 
Mannitol Sigma Aldrich M4125 
Dodecane Sigma Aldrich 297879 
96-well Plates Celltreat 229596 
Yeast Carbon Base Sigma Aldrich Y3627 
Ammonium Acetate Sigma Aldrich A1542 
Sodium Nitrate Sigma Aldrich S5506 
Sodium Nitrite Sigma Aldrich 237213 
Urea Sigma Aldrich U0631 
L-arginine Sigma Aldrich A5006 
L-valine Sigma Aldrich V0500 
Glycine Sigma Aldrich 410225 
L-proline Sigma Aldrich P0380 
D-valine Sigma Aldrich 855987 
Uracile Sigma Aldrich U0750 
Thymine Sigma Aldrich T0376 
Thiamin Hydrochloride Sigma Aldrich T4625 
Pyridoxin Hydrochloride Sigma Aldrich P9755 
Biolog Universal Yeast Agar Biolog 70005 
Turbidimeter Biolog 3587 
Biolog YT Standard Biolog 3415 
YT Microplate Biolog 1005 
Reservoirs MedSupplyPartners 62-1012-6 
Flucytosine b ApexBio A8433 
Micafungin ApexBio A3606 
Fluconazole Sigma Aldrich F8929 
Amphotericin b Sigma Aldrich A9528 
Dimethyl Sulfoxide Sigma Aldrich D4540 
Coriander Seed Essential Oil Mountain Rose Herbs eo_co1/2 
Ginger Essential Oil Mountain Rose Herbs eo_gi1/2 
Eucalyptus Essential Oil Mountain Rose Herbs eo_eu1/2 
Geranium Essential Oil Mountain Rose Herbs eo_ge1/2 
Tea Tree Essential Oil Mountain Rose Herbs eo_tto1/2 
Peppermint Essential Oil Mountain Rose Herbs eo_pep1/2 
Lemongrass Essential Oil Mountain Rose Herbs eo_lg1/2 
Cinnamon Bark Essential Oil Mountain Rose Herbs eo_cb1/2 
Orange, Bitter Essential Oil Mountain Rose Herbs eo_or_b1/2 
Grapefruit Essential Oil Mountain Rose Herbs eo_gr1/2 
Clove Bud Essential Oil Mountain Rose Herbs eo_clo1/2 
Spearmint Essential Oil Mountain Rose Herbs eo_sp1/2 
Basil Essential Oil Mountain Rose Herbs eo_ba1/2 
Bergamot Essential Oil Mountain Rose Herbs eo_be1/2 
Cinnamon Leaf Essential Oil Mountain Rose Herbs eo_cl1/2 
Frankincense Essential Oil Mountain Rose Herbs eo_fr1/2 
Lavender Essential Oil Mountain Rose Herbs eo_la_o1/2 
Lemon Essential Oil Mountain Rose Herbs eo_le1/2 
Lime Peel Essential Oil Mountain Rose Herbs eo_lp1/2 
Manuka Essential Oil Mountain Rose Herbs eo_manu1/2 
Myrrh Essential Oil Mountain Rose Herbs eo_mro1/2 
Breathable Sealing Film Diversified Biotech BEM-1 
Methylene blue EK industries EK-7161 
Malt extract Acumedia 7341A 
Agar EMD Millipore EM-140500 
Hemocytometer Brightline 400180 
Hemocytometer LW Scientific MKT-7.5.3L120 
Spectrophotometer VWR UV6300PC 
Microscope Motic BA410E 
Biolog Microstation Biolog 65361 
Microlog 3 Software Biolog V 5.2.1.35 
Plate Reader Biotek SynergyH1 
Gen5 Software Biotek V2.01 






Appendix V: Media and Solution Recipes  
  
Malt Extract Broth (MEB): 30 grams Malt Extract per 1.0 L deionized water 
Malt Extract Agar (MEA): 30 grams Malt Extract & 20 grams Agar per 1.0 L deionized water 
Conidia Harvesting Solution (CHS): 0.05% Tween 20 & 0.9% sodium chloride in deionized 
water. 
Yeast Nitrogen Base without amino acids (YNB): 6.8 grams dehydrated YNB powder per 1.0 L 
deionized water. Supplement with 2.0% of selected carbon source. 
YNB plus Glucose (YNBG): 6.8 grams dehydrated YNB powder per 1.0 L deionized water. 
Supplement with 20 grams of Glucose. 
Yeast Carbon Base (YCB): 11.7 grams dehydrated YCB powder per 1.0L deionized water. 
Supplement with 2.0% selected nitrogen source. 
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